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ABSTRACT
CARNOSINE, A THERAPEUTIC POTENTIAL FOR CRITICAL LIMB ISCHEMIA
Adjoa Agyemang Boakye
July 27th, 2016
Critical Limb ischemia (CLI) is a serious manifestation of peripheral artery disease.
Advanced CLI patients are poor candidates for vascular surgeries. Numerous
studies have shown that hypoxia inducible factor 1α (HIF1-α) plays an important
role in recovery from murine hindlimb ischemia (HLI). HIF1-α is regulated by
oxygen dependent prolyl hydroxylases (PHDs). Previous studies have shown that
inhibition of PHDs by metal quenchers and viral delivery of HIF1-α improves blood
flow to the ischemic limb. However, clinical trials with these therapies are largely
negative partly because they do not address the underlying chronic oxidative
stress. Based on recent observations that endogenous histidyl dipeptides such as
carnosine can chelate metals and quench reactive carbonyls, we hypothesize that
supplementation of carnosine can promote revascularization to enhance wound
healing through aldehyde quenching and metal chelation. C57BL/6 mice were
subjected to hindlimb ischemia (HLI) surgery by ligating the femoral artery and vein
and supplemented with carnosine (1g/L) for 21 days. Laser Doppler analysis
showed that blood flow in carnosine treated mice was significantly increased
(31±2%) compared with the non-treated mice (20±2%) after 14 and 21 days
v

(carnosine 50±6% vs non-treated 28±4%; p<0.05) of recovery from surgery.
Vascular density measured by microfil-perfusion-microCT was significantly
enhanced by carnosine treatment compared with non-treated HLI mice. Similarly,
muscle regeneration and isolectin staining was significantly increased compared
to the non-treated mice. Mobilization of endothelial progenitor cells (Flk+/Sca+) and
VEGF expression in the ischemic limb was significantly increased by carnosine
supplementation. Also, 4-HNE protein adduct levels were decreased in ischemic
limbs of carnosine treated mice. Levels of carnosine in the ischemic muscle were
increased approximately 2 fold compared with non-treated HLI mice. Pretreatment of C2C12 cells with carnosine and its analogue methyl carcinine, that
lacks the ability to quench metals, resulted in increased nuclear levels of HIF1-α
and VEGF secretion in hypoxic carnosine treated cells compared with methyl
carcinine treated hypoxic cells.

Collectively, our results demonstrate that

carnosine treatment improves blood flow by increasing HIF1-α stabilization and
endothelial progenitor cell mobilization thus, can be used as a safe therapeutic
intervention for CLI patients
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CHAPTER I
GENERAL INTRODUCTION
Epidemiology of Peripheral Artery Disease
Recent epidemiological data estimates that non-communicable chronic diseases
are the leading cause of morbidity and mortality worldwide [1]. This burden is
expected to rise within the next decades because of an increase in exposure to
risk factor for these diseases [2]. Therefore efforts have to be put in place to identify
risk factors as well as cost-effective treatment and preventive strategies to combat
this burden. One best example of this chronic disease condition that is often
underdiagnosed is peripheral arterial disease.
Peripheral arterial disease (PAD) refers to narrowing or complete atherosclerotic
occlusion of one or more upper or lower extremity artery [3].

Although this

definition covers arterial disorders other than the coronary vasculature, most
reports and guidelines limit it to occlusive diseases in branches of the lower aorta
[4]. It’s important to note that non-atherosclerotic PAD such as fibromuscular
dysplasia and vasculitis, although rare, also exist [5]. Atherosclerotic PAD is
estimated to affect > 200 million people worldwide and approximately 8 million
people in the United States [2, 6]. Even though PAD represents a distinct disease
state it is also a predisposing factor for coronary artery and cerebrovascular
disease [7, 8]. PAD is also the leading cause of morbidity due to the associated
1

decline in limb function as well as limb loss in certain individuals [9]. Recently, the
Institute of Medicine has listed PAD as a high research priority area to reduce
mortality and morbidity associated with PAD [10].
The classical symptom for PAD is intermittent claudication which is leg pain
resulting from walking or exercise that is relieved at rest [7].This pain occurs
because during walking or exercise metabolic demands of the limbs are not met
due to the narrowing of blood vessel thus, limiting the capacity of the circulatory
system [2, 11]. This deficit in blood supply exerts the same discomfort as angina
for coronary heart disease resulting in calf muscle cramping and fatigue [12]. Most
patients with PAD may not exhibit any symptoms of intermittent claudication
because they do not subject themselves to exertional exercise, or the
atherosclerotic plaque is not sufficient to elicit any hemodynamic burden. Current
estimates show that only 10-20% of patients presents with intermittent claudication
and the remainder are either asymptomatic or present with symptoms that are
atypical [13, 14]. This high prevalence of asymptomatic leg ischemia and exertional
pain other than intermittent claudication may explain why PAD is often
underdiagnosed. Progressive unabated atherosclerotic burden in PAD results in
critical limb ischemia (CLI). CLI is the most severe form of PAD which manifests
as ischemic rest pain, gangrene, necrosis and ulcers. CLI is associated with high
rates for limb amputations and death [15].
Due to the limitations associated with using intermittent claudication as a
diagnostic tool, ankle brachial index (ABI) is routinely used in clinical practice as a
diagnostic tool. ABI refers to ratio of systolic pressure at the ankle to that in the
2

arm. An ABI value of <0.9 is defined as PAD while values between 0.9 and 1
represents borderline values [7]. Values > 1 are considered normal however, in
patients with calcified noncompressible lower extremity arteriopathy, ABI values >
1.4 have been reported [16]. Although ABI is highly specific it has a low sensitivity
[17]. This is partly due to the fact that ABI only becomes abnormal with significant
hemodynamic lesions and diseases of less severity might not be detected [18].
Imaging techniques such as Doppler ultrasound and angiography are employed
as diagnostic tools but each of these imaging techniques has their limitations of
being either invasive or not providing accurate measurements of the
atherosclerotic burden [19]. The lack of good diagnostic tools and clearly defined
symptoms explains why for some patients the first manifestation of PAD is critical
limb ischemia.
The risk factors for PAD are same as traditional risk factors for cardiovascular
disease such as cigarette smoking, diabetes mellitus, hypertension, dyslipidemia
and ageing [19-21]. Amongst these risk factors smoking is considered to be the
strongest predictor for PAD. Studies have shown that smoking plays a prominent
role in PAD compared to other atherosclerotic diseases and cessation of smoking
reduces the risk of PAD associated morbidity and mortality [7, 22]. In addition to
smoking, ageing is also a potent risk factor for PAD. Recent studies suggest that
up to 15% of the adult population (i.e. > 45 years) have PAD [6, 23] and the
incidence of age driven PAD is likely to increase [2]. Diabetes mellitus is another
important risk factor for PAD. Studies with human diabetics have shown that 1%
increase in glycosylated hemoglobin increases the incidence of PAD by
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approximately 28% [24]. Diabetes also affects the anatomic distribution of disease
leading to a bad prognosis in these individuals [25, 26]. Dyslipidemia and
hypertension, though risk factors, contribute less to the pathogenesis of PAD as
compared to other vascular events such as myocardial infarction and ischemic
stroke [23]. Family history of PAD has also being shown to be a predisposing
factor. This is partly due to inheritability of risk factors such as dyslipidemia and
diabetes mellitus [18]. Further research into the genetics of PAD may reveal other
candidate genes which may act as prognostic markers for PAD. Other risk factors
such as obesity, homocysteinemia, C-reactive protein, race and ethnicity have not
been studied in details but there are evidences to suggest that they contribute to
PAD development [7].
Pathophysiology of peripheral artery disease
The pathophysiology of atherosclerotic PAD is complex involving chemokines,
growth factors, cytokines, signaling molecules and different cell types [9, 27-29].
Atherosclerosis, the underlying cause of PAD, refers to buildup of fatty plaques in
blood vessels that limits blood flow to the target organs. Exposure of vascular cells
to lipoproteins triggers a series of reactions involving endothelial cells, vascular
smooth muscle cells and the innate immune system. A cascade of events results
in foam cell formation, cell death, calcification and arterial remodeling, that
progressively leads to narrowing of the blood vessel [30, 31]. Imaging results from
PAD patients show narrowing of lower aorta, femoral, iliac, popliteal and tibial
arteries [12, 16]. This narrowing causes intermittent claudication in some
individual, but majority of PAD patients are usually asymptomatic [23, 32]. The
4

hemodynamic changes associated with these occlusion are diagnosed as a
reduction in ankle brachial index and is dependent on the location of the occlusion
and existence of blood vessels other than the occluded vessel linking the
preoccluded and postoccluded sites [9]. Ultimately, supply of nutrients and oxygen
to the metabolically active skeletal muscle tissue distal to the site of occlusion is
hampered resulting in tissue ischemia.
Prolonged ischemic insult results in skeletal muscle dysfunction that ultimately
leads to tissue death and necrosis due to accumulation of toxic metabolites,
decrease in intracellular pH, shift to anaerobic metabolism, and ultimately

a

reduction in cellular energy charge [33]. Although restoring blood flow to the
ischemic limb is essential to salvage and restore limb metabolic activity,
reperfusion is also detrimental to the muscle [34-36]. The exact mechanisms
involved in reperfusion injury are not clear, however, several studies have shown
that restoration of molecular oxygen exacerbates reperfusion injury. Studies by
Korthuis et al. showed that reperfusion with normal blood causes microvascular
dysfunction and myocyte necrosis, however, this effect was attenuated when the
skeletal muscle was perfused with anoxic blood [37, 38]. Similarly, studies showing
that antioxidant enzymes such as superoxide dismutase and glutathione
peroxidase or their mimetics and free radical scavengers exhibit protective effects
in hindlimb ischemia and clearly demonstrate a causal role of oxygen derived
reactive metabolites in the pathogenesis of reperfusion injury [39-41].
PAD patients experience several bouts of ischemia and reperfusion. During
walking or exercise, metabolic demands of muscle exceed oxygen supply due to
5

arterial narrowing mimicking ischemia and during resting periods, reperfusion
occurs in the ischemic limbs. Unlike the heart or brain, atherothromobotic events
in the muscle do not cause acute conditions like myocardial infarction or stroke
and the mechanism underlying these tissue specific responses to ischemia are not
clear. Repeated bouts of ischemia and reperfusion results in ion pump
dysregulation, mitochondrial dysfunction, ROS generation, inflammation and
apoptosis. These processes if unrestricted result in damage to the muscle fibers
[9, 23, 32].
Ischemia reperfusion is followed by the reparative phase that involves stimulation
of pathways to ensure repair of damaged tissue and restore organ function [42].
During this stage ROS production occurs in limited amounts which serve as
signaling molecules. Minute production of ROS activate transcription of growth
factors such as vascular endothelial growth factor (VEGF) that results in
revascularization and tissue regeneration [43, 44].

Bone marrow derived

mononuclear cells also play an important role in this reparative process [45-48].
However, these adaptive responses are hindered in patients with PAD. Although,
most of the pathways elicited in the reparative phase are aimed to restore organ
function, chronic activation of these reparative processes contribute to organ
failure due to fibrosis [42]. Thus, the symptoms can progress from intermittent
claudication to rest pain to chronic non-healing ulcers and culminate in gangrene
and eventual amputation.

6

Ischemic Phase Injury
Ischemic insult to a tissue results in tissue hypoxia due to limited or inadequate
supply of oxygen. The absence of oxygen prevents aerobic metabolism through
the mitochondria resulting in the reliance on anaerobic glycolysis for energy
generation [49]. Due to the low efficiency of glycolysis in utilization of cellular
energy sources, the decrease in mitochondrial metabolism depletes ATP levels
and decreases cellular pH due to accumulation of H+ ions. Additionally, fatty acid
catabolism is decreased due to depleted oxygen levels which results in
accumulation of harmful lipids [50, 51]. The absence of an effective circulatory
system not only limits the availability of oxygen but also decreases the extrusion
of toxic metabolites from the cell. To restore pH to its normal levels, the cell
increases extrusion of H+ leading to increased intracellular transport of Na+ through
Na+/H+ exchanger. Because ATP production is decreased during ischemia, ATP
regulated ion pumps such as Na+/ K+ ATPase, that maintains low intracellular Na+,
is inhibited resulting in increased intracellular Na+ [42, 52]. The increase in
intracellular Na+ decreases the concentration gradient across the membrane which
increases the outward movement of Na+ through the Na+/ Ca2+ exchanger thereby
reversing the function of this exchanger in resting membranes and increasing
intracellular calcium (Fig. 1) [42].
Intracellular calcium levels are tightly regulated by the Na+/ Ca2+ exchanger and
Ca2+ ATPase which regulates transport across the plasma membrane. Likewise,
the ryanodine receptors and ATP- dependent SERCA which functions to regulate
sarcoplasmic reticulum calcium transport can affect intracellular Ca2+ levels [53,
7

54]. During ischemia Na+/ Ca2+ exchanger activity is increased, intracellular
calcium levels are elevated and extracellular transport through the membrane
bound Ca2+ ATPase or transport to the sarcoplasmic reticulum through SERCA
are both decreased due to depleted ATP levels [55]. This phenomenon of
increased intracellular calcium concentration during ischemia is referred to as
calcium overload. With the increase in intracellular uptake and diminished uptake
into the calcium storing organelle (sarcoplasmic reticulum), mitochondrial transport
of Ca2+ is increased which limits oxidative phosphorylation. The increase in
intracellular Ca2+ also activates Ca2+ dependent proteases, phosphatases and
phospholipases such as protease calpains which degrade cytoskeletal and
endoplasmic reticulum proteins leading to cell death [56]. Furthermore,
phospholipase activation leads to membrane phospholipid degradation and
accumulation of free fatty acids such as arachidonic acid, a prostaglandin inducer.
Since membrane phospholipids are important in maintaining membrane structure
their degradation disrupts membrane integrity and potentiates the loss of ion
pumps and membrane bound receptors [57].
In addition to the above mentioned pathway, ischemia also activates pathways
which do not contribute directly to the ischemic phase injury but lay the foundation
for reperfusion injury e.g., conformational changes in oxidant producing enzymes,
such as xanthine oxidase is induced by the increase in proton generation in
ischemia [58, 59].
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Figure 1

9

Figure 1: Mechanisms contributing to ischemia/reperfusion induced tissue
injury: Ischemia resulting from arterial occlusion leads to increased anaerobic
respiration. The ensuing acidosis and reduced ATP levels results in increased
intracellular Ca2+. ATP hydrolysis also leads to the accumulation of hypoxanthine,
a substrate of xanthine oxidase (XO). Dysfunctioning of electron transport chain
(ETC) and activation of enzymes capable of producing ROS are also initiated.
During reperfusion, the return of oxygen leads to exuberant ROS production. ROS
could result from xanthine oxidase (XO) which produces superoxide anion as a
by-product of hypoxanthine catabolism. NAPDH oxidase (Nox2), and mitochondria
represent other sources of ROS during reperfusion. ROS generation results in
eNOS uncoupling due to decreased intraceullar BH4 levels. This leads to decrease
levels of antiahesive NO and subsequent invasion of phagocytic cells.
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Reperfusion Injury
During reperfusion, return of molecular oxygen to the ischemic tissues aggravates
tissue injury initiated by the initial ischemic insults. Because reperfusion phase of
the disease is amendable to treatment it represents a valuable step to study.
Although, research over the past decades has improved our understanding of the
molecular processes involved in this injury, the exact mechanisms are not
completely understood. Numerous studies have shown that ROS generation
during reperfusion is the pivotal casual factor in reperfusion injury [33, 42] . ROS
are documented to initiate pathways that lead to leukocyte infiltration, inflammation
and mitochondrial permeability pore transition [49, 60, 61].
ROS can reacts with lipids to generate highly reactive lipid peroxidation product
such as acrolein and 4hydroxynonenal (4HNE) [62]. ROS can also modify
functional groups of proteins and can induce damage to DNA [60, 61]. Although
extensive research has been conducted to examine the role of ROS regulators
e.g., enzymes, mimetics, antioxidants and free radical scavengers as therapeutic
interventions in ischemic related diseases such as PAD, the molecular
mechanisms underlying reperfusion injury is not fully understood.
Sources of reactive oxygen species during reperfusion
Oxygen is like a two-edged sword that increases our efficiency in utilization of
energy deriving substrate but also results in the generation of ROS that cause
tissue damage. Under physiological conditions ROS are generated by enzymes
such as xanthine oxidase, NADPH oxidase and the electron transport chain [33].
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Xanthine oxidase(XO) is a key enzyme of purine catabolism pathway which can
exist in two forms; an NAD+-dependent dehydrogenase or oxygen dependent
oxidase form [58]. During ischemia the dehydrogenase isoform is converted to the
oxidase isoform through either proteolysis of a small portion of the enzyme or
oxidation of a thiol residue in the enzyme [58, 63, 64]. Moreover, ischemia results
in increased degradation of ATP to adenosine, which is deaminated into
hypoxanthine, a substrate of xanthine oxidase [33, 65]. The increase in substrate
availability primes the enzyme so that once molecular oxygen is provided during
reperfusion there is an increase in its catalytic activity resulting in superoxide
generation. Studies have shown that xanthine oxidase activity is increased during
reperfusion [66]. Additionally, inhibition of xanthine oxidase by inhibitors such as
allopurinol prevents reperfusion injury thus establishing a role for xanthine oxidase
in reperfusion-induced ROS production [66].
During reperfusion injury NADPH Oxidase contributes to superoxide anion (O2-)
generation. Different isoforms of this enzyme are expressed on leukocytes,
endothelial cells and mitochondria [67, 68]. All isoforms of this enzyme catalyze
the formation of O2- using NADPH as substrate [68]. Unlike the neutrophilic isoform
which is activated during infection or tissue damage the vascular isoform, Nox 4,
produces low amount of O2- to maintain normal vascular tone through endothelial
nitric oxide synthase (eNOS) activation [69]. However, under ischemic conditions
even the vascular isoform increases the generation of O2- which is augmented by
superoxide production from infiltrating granulocytes [49, 68, 70, 71].
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Under physiological conditions oxygen is reduced to water by the electron
transport chain however, approximately 2% of molecular oxygen is partially
reduced which generates O2- [42, 72]. Mitochondria contributes to 95% of ROS
generated under physiological conditions [42]. ROS in the mitochondria are
generated primarily from electron leaks in complexes I and III and this
phenomenon is increased during reperfusion [42, 73, 74]. This reperfusion
associated exuberant ROS production can result due to redox sensitive ironsulfurs of the mitochondria complexes undergoing oxidation/reduction reactions
[75], nitration of complexes I and III and disruption of cardiolipin-respiratory chain
super assemblies in complexes I – III [76-78] culminating in loss of activity of these
complexes.
In addition to the leaks in the electron transport chain, O2-

is generated by

monoamine oxidase, growth factor adapter Shc, and mitochondrial Nox 4 [42, 49].
These enzymes are activated through ischemia mediated increased availability of
substrate, changes in enzyme conformation or subcellular localization [42].
Furthermore, mitochondrial generated O2- can leak into cytosol, activate
mitochondrial anion channel and result in mitochondrial permeability transition
[79].
In addition to these ROS generating systems endothelial nitric oxide synthase
(eNOS) uncoupling also generates ROS during reperfusion injury. eNOS catalyzes
the reaction that leads to the production of vasodilatory and antiadhesive
compound, nitric oxide, and requires tetrahydrobiopterin (BH4) as a cofactor. BH4
transfers electrons from oxygen to arginine leading to formation of L-citrulline and
13

NO. During reperfusion O2- oxidizes BH4 [80, 81] which diminishes BH4 shuttling
capacity leading to eNOS uncoupling and additional O2- production. BH4 levels are
reduced during ischemia/reperfusion (I/R) injury and treatment with BH4 protects
from I/R injury [80]. O2- can also react with NO and generate highly reactive
nitrosative product [49] Thus, increased ROS generation trigger more ROS
production thereby increasing the oxidative stress burden. Fig. 1 provides a
summary of ROS sources during reperfusion.
Mechanisms of oxidant-mediated cellular injury
ROS can attack the entire array of biomolecules found in the body causing damage
to these biomolecules [82]. These damaging effects can occur due to ROS induce
peroxidation of membrane lipid, protein crosslinking or degradation, and DNA
hydroxylation [49]. These direct effects of ROS could explain some of the
phenotype observed during reperfusion. For example peroxidation of membrane
lipids affects membrane fluidity and barrier functions which then leads to electrolyte
accumulation, cell volume dysregulation, cellular edema and eventual lysis of
myocytes [33].

Lipid peroxidation of enzymes can lead to loss of function,

modification of enzyme function or even target the enzyme for degradation. For
instance oxidative inactivation of the Krebs cycle enzyme aconitase results in the
production of hydroxyl radicals by the enzyme thus, enhancing the oxidative stress
already present [83]. In addition, second messenger generation could occur due
to peroxidation which then disrupt cellular signaling pathways and activates cell
death pathways in some instances [84]. ROS can increase the frequency of
mutations in DNA and cause changes in transcript sequences accounting for
14

aberrant protein synthesis. These changes in protein synthesis activate the
unfolded protein response leading to endoplasmic reticulum stress and cytotoxic
pathway activation [85]. ROS also appear to play a role in the increased
microvascular permeability associated with reperfusion of ischemic skeletal
muscle. This notion is supported by the observation that administration of free
radical scavengers attenuates reperfusion induced microvascular permeability [38,
86].
Mitochondrial ROS generation can lead to mitochondrial permeability transition
thereby allowing leakage of mitochondrial contents into the cytosol. For instance
leakage of cytochrome c into the cytoplasm can activate proapoptotic signaling
pathways [42, 49]. Mitochondrial DNA is particularly susceptible to ROS induced
damages due to the lack of protection by histones, unavailability of adequate DNA
repair machineries, and proximity to ROS producing sites [42]. Infiltration of
activated neutrophils also generate ROS such as hypochlorous acid and
superoxide in addition to secretion of hydrolytic factors which results in further
tissue injury [33].
Inflammation
Inflammation refers to a complex pathologic response involving an intricate and
highly dynamic sequence of events that occurs in affected blood vessels and
adjacent tissues in response to an injury or infection. Both infection and injury have
been shown to elicit a similar immune response. In the early 1990, Matzinger
proposed the danger theory to explain an immune response that encompasses
both the response to infection and injury. The danger theory states that an immune
15

response is triggered by danger signals released by the body’s own cells and that
the presence of non-self is not sufficient to elicit the immune response [87]. Under
stressed conditions such as ischemia, the immune response can be triggered by
modification of intra-cellular components e.g. it has been shown that during
ischemia calcium overload leads to calcium pyrophosphate complex formation.
Also, uric acid accumulates due to xanthine oxidase activation. Both calcium
pyrophosphate complex and uric acid have the abilities to bind and activate the
inflammasome [88, 89]. Inflammasomes are intracellular protein complexes that
mediate the production of cytokines such as TNF-α, activate inflammatory
signaling pathways such as NF-kb, as well as activate proapoptotic caspases [88].
These cytokines attract neutrophils to the site of injury.
A large body of evidence suggests that ROS is involved in leukocyte recruitment.
Endothelial cells or isolated blood vessels that were exposed to H2O2 became
more adhesive to neutrophils [90, 91] which is, in part, mediated by depleted NO
levels [92, 93]. Additionally, chemoattractant molecules such as platelet activating
factor and leukocyte B4 receptor are upregulated by ROS [33]. Furthermore, ROS
also activates complement system that increases neutrophil recruitment [33].
Direct causal relationship between ROS production and neutrophil infiltration has
been established by using antioxidant enzymes or ROS scavengers which
diminishes neutrophil infiltration in both cultured cells and animal studies [33].
Neutrophils cause injury by releasing enzymes such as collagenase and elastase
which degrade the basement membrane of capillaries [33]. They also secrete
oxidants such as hypochlorous acid that increases protease levels which
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exacerbate inflammation by activating cytokine production [94, 95]. The direct
evidence showing that neutrophils are causal in the inflammation process is
provided by studies showing that microvascular dysfunction is attenuated in
animals that are rendered leukopenic [96, 97]
Neutrophil recruitment to ischemic tissues
Leukocyte recruitment to the ischemic tissue is a complex series of event that
involves a number of adhesive molecules [96, 98]. Using gain and loss of function
studies several mediators on both the endothelial cell and granulocytes have been
shown to play pivotal role in these processes. For instance neutralizing antibody
against common β- subunit (CD18) on neutrophils or P-selectin on activated
endothelial cell prevents neutrophil adhesion and migration [99]. Additionally,
adhesive molecules such as ICAM- 1 are also important in mediating interactions
with CD18 which provide an avenue for direct transfer of neutrophilic content to
the muscle [100]. CD18/ICAM-1 adherence reactions contribute to microvascular
barrier disruption, which allows transmigration of neutrophils to the skeletal muscle
[101, 102]. This observed upregulation in the levels of pro-adhesive molecules
occurs in the presence of decreased NO levels, which accentuates the activated
adhesive endothelial phenotype. Studies that disrupted the adhesive interactions
between neutrophil and endothelium have demonstrated a decline in neutrophildependent cell injury. Likewise, establishment of these interactions not only allows
the phagocytic cells to migrate to sites of inflammation but also appears to facilitate
the destructive potential of the granulocytes [103, 104]. Neutrophil-endothelium
interactions are therefore essential for immigration of activated leukocytes. In
17

addition to these interactions, modifications are induced in the cytoskeletal
structure of the endothelium which modulates the transmigration process [105].
This close proximity of neutrophils to endothelial cells is required for the production
of leukocyte dependent injury since adherent neutrophil have an increased oxidant
release capacity than suspended neutrophils [33].
Capillary no-reflow phenomenon
Reperfusion does not always lead to restoration of tissue perfusion but could lead
to a condition referred to as capillary no-reflow. Capillary no-reflow is defined as a
suboptimal tissue perfusion without any evidence of vessel obstruction due to
atherothrombosis [49]. Although poorly understood, studies show a direct
correlation between leukocyte numbers and the percent of no-reflow capillaries.
Depletion of neutrophils also abolishes no-reflow in reperfused tissues [49, 102,
106] implying that neutrophils and ROS are involved in capillary no reflow.
This phenomenon of capillary no-reflow is initiated as a result of ROS and
granulocyte

mediated

proinflammatory

milieu

generation

and

ion-pump

dysfunction. The proinflammatory stimuli lead to modification of adhesive
molecules on both neutrophils and endothelial cells. Leukocytes then roll on the
endothelial surface, get tethered and eventually egress into the underlying tissue.
This phenomenon results in endothelial barrier dysfunction allowing enhanced
vascular protein leakage. The ensuing increased transcapillary fluid filtration
results in edema and increased interstitial pressure. Edema exerts physical
compression on the vessel especially for tissues such as muscles, which cannot
readily expand due to the presence of a restrictive fascial sheath, resulting in the
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capillary no-reflow phenomenon [33, 49]. Altered ion pump function is partly
responsible for edema formation and reducing edema by treatment with a
hyperosmotic saline dextran solution prevents endothelial cell swelling [107]
Reparative Phase
This response phase to ischemic insult involves activation of processes that seek
to restore tissue perfusion and heal the damage tissue. Three key processes are
involved in the revascularization responses namely vasculogenesis, angiogenesis
and arteriogenesis (Fig.2). Although these processes are distinct in some aspects
they do share overlapping mediators such as growth factors and cytokines.
Furthermore, one process could influence the subsequent process i.e.
vasculogenesis could lead to angiogenesis. Tissue regeneration and repair is a
sequel of revascularization that involves growth factors, tissue resident stem cells
and bone marrow derived stem cells
Angiogenesis
Angiogenesis is a well-studied process that involves proliferation, sprouting and
migration of endothelial cells to form new thin walled capillaries [108]. The initial
trigger for angiogenesis is local ischemia. In 1988 Goldberg and colleagues while
examining the expression of erythropoietin gene observed that hypoxia, cobalt
chloride or nickel chloride increased mRNA expression of erythropoietin through a
common pathway [109]. They hypothesized that this common pathway involved a
ligand dependent conformational change in a heme containing protein. Later
Semenza et al. identified a cis-acting enhancer element in erythropoietin gene and
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a multimeric transcriptional regulatory complex which binds directly to a 50-base
pair hypoxia-inducible enhancer element in the 3’ region of erythropoietin gene.
These transcription factors were referred as hypoxia inducible factor (HIF) [110,
111].
The HIF family transcription factors are now known to include three constitutively
expressed β-isoforms, whose regulations are oxygen independent, and at least
three oxygen-dependent α-isoforms [112]. Of the three α-isoforms, HIF1-α is the
most ubiquitously expressed whereas HIF2-α and HIF3-α are more restricted to
specific tissues [113]. All three isoforms have been shown to interact with the βisoforms and activate target gene transcription [114, 115]. However, an alternately
spliced transcript of

HIF3-α, inhibitory Per-ARNT-Sim (PAS) domain protein,

appears to be a negative regulator of transcription [116]. Due to the ubiquitous
nature of HIF1-α, it is the most widely studied isoform.
HIF1-α is a basic helix-loop helix (bHLH), Per-ARNT-Sim (PAS) domain containing
protein. It contains an oxygen-dependent degradation and transactivation
domains. The basic helix-loop helix domain is essential for its DNA binding activity
whereas the PAS domain is involved in heterodimerization with HIF-β. The oxygen
dependent degradation and transactivation domains regulate HIF1-α stability and
coactivator binding respectively [113, 117].
Initially it was thought that the putative HIF1-α regulator was a heme iron
containing protein, but further studies established that stabilization of HIF1-α is
mediated by non heme containing enzymes identified as prolyl hydroxylases
(PHDs). PHDs are iron-containing dioxygenases that require α-ketoglutarate and
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oxygen for their activity [118]. The discovery of PHDs and HIF1-α helped us better
understand the role of molecular oxygen in the molecular mechanisms that are
activated during hypoxia. In the presence of molecular oxygen HIF1-α is targeted
for proteasomal degradation through PHD mediated hydroxylation of two essential
proline residues in the oxygen dependent degradation domain. The reaction
requires Fe2+, α-ketoglutarate and oxygen and involves splitting molecular oxygen
into two. One oxygen is used as a substrate for hydroxylation and the other used
for oxidation of α-ketoglutarate to succinate [119]. Hydroxylation on the proline
residues act as a specificity determinant allowing for recruitment of the E3 ubiquitin
ligase, von Hippel-Lindau tumor suppressor (pVHL), thereby targeting HIF1-α for
proteasomal degradation. Each of the hydroxylation sites can independently
interact with VHL potentially contributing to rapid degradation of HIF1-α [116].
However, under hypoxic conditions when oxygen becomes limiting PHD activity is
inhibited thereby preventing proline residue hydroxylation on HIF1-α [118].
Furthermore, Fe2+ in the catalytic site of the enzyme is loosely bound to 2-histidine1- carboxylate coordinate motifs which makes Fe2+ susceptible to displacement
[113]. Therefore, metal chelators such as deferoxamine can induce HIF1-α
stabilization even in the presence of molecular oxygen [120, 121].
In addition to this modification, hydroxylation of an asparagine residue in the
transactivation domain by asparagine hydroxylase prevents interactions with
coactivators [116]. Other posttranslational modifications such as acetylation and
phosphorylation have been shown to occur in HIF1-α. Acetylation of a conserved
lysine residue in the oxygen degradative domain has been shown to be important

21

in HIF1-α-pVHL interactions and stability. Also, phosphorylation by MAPK is
reported not to affect stability or transactivation but rather increase HIF1-α
transcriptional activity [113, 122, 123]. Other less common modifications are
SUMOylation which activates and represses transactivation and cysteine residue
S-nitrosation which increases transactivation [124-127]. Cytokines, ROS and
growth factors could also activate HIF-1α in a hypoxia independent manner [113,
117]. However, studies have shown that prolyl hydroxylation is the most important
regulator of HIF1-  stability.
Once proline residue hydroxylation is inhibited under hypoxic conditions, HIF1-α
translocate into the nucleus and interacts with its coactivators. This transcriptional
complex is formed on genes that contain the cis-acting element that was initially
identified in the erythropoietin gene. Using promoter analysis on genes that are
modified by hypoxia this consensus sequence, referred to as hypoxia response
element (HRE), has been shown to be present in hundreds of genes involved in
erythropoiesis, Fe2+ metabolism, angiogenesis, glycolysis, immunity, cell
proliferation, and matrix and barrier regulation [113]. The ability of this single factor
to regulate these diverse genes involved in almost all the adaptations to hypoxia
makes its regulation a viable target in the treatment of ischemic pathologies.
The genes involved in angiogenesis that are regulated by HIF1-α, include
epidermal growth factor, platelet-derived growth factor, angiopoietin, stromalderived growth factor and vascular endothelial growth factor (VEGF) which is the
most potent endothelial specific mitogen [108, 128].
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VEGF family of growth factors consists of seven family members named VEGFA F and PIGF with VEGF-A being the prototype. With the exception of VEGF-F and
PIGF all five VEGF family members exist in mammalian cells [129]. These are a
family of secreted proteins each containing a cysteine-knot structure with eight
invariant cysteine-residues that are involved in inter and intra molecular disulfide
bond formation [130]. The angiogenic effects of secreted VEGF are propagated by
binding with the VEGF tyrosine kinase receptors. Three VEGF tyrosine kinase
receptors designated VEGFR1-3 have been identified. Each receptor has a single
membrane-spanning

region,

seven

immunoglobulin-like

domains

in

the

extracellular region and a conserved tyrosine kinase sequence interrupted by a
kinase insert domain [130]. VEGFR2 appears to be the most important receptor in
VEGF-mediated proliferation of endothelial cells [131]. On the other hand VEGFR1
is likely involved in negative regulation of VEGFR2 mitogenic effects [132].
VEGFR3 is usually limited to lymphatic endothelial cells and seems to regulate
proliferation and migration of these cells. In terms of its activation it differs from the
other two VEGFRs because it undergoes proteolytic cleavage in the extracellular
domain into two disulfide linked polypeptides [129].
Binding of VEGF to VEGFR2 results in autophosphorylation of several tyrosine
residues in the kinase-insert domain and C-terminal domain. Each of these
autophosphorylation site mediates specific interactions between receptors and
downstream signal transducers [129]. In human’s tyrosine1175 phosphorylation
creates a docking site for phospholipase C-γ1 (PLCγ1), growth factor receptorbound protein 2 and SHC. PLCγ1 docking leads to activation of protein kinase C
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through diacylglycerol generation from phosphatidylinositol 4, 5-bisphosphate.
Diacylglycerol is known to activate MAPK cascade which promotes cell survival
and proliferation. This pathway also lead to Ca2+ signaling, prostaglandin
production and increased vascular permeability [133]. Another signaling pathway
which can be activated is the PI3K signaling cascade. Docking of PI3K to phospho
tyrosine leads to activation of protein kinase B (PKB)/AKT leading to
phosphorylation of proapoptotic caspase 9 and BAD which inhibits proapoptotic
factors and increase proliferation and survival. PKB/AKT pathway also increase
eNOS activity through interaction with HSP90 and leads to increased vascular
permeability [129, 133]. Modifications in focal adhesion proteins are also induced
through SRC and SHB docking. This causes actin reorganization facilitating
endothelial and smooth muscle cell migration which are necessary for
angiogenesis. The immune/ inflammatory pathways are also activated by VEGF
signaling through the JAK/STAT pathway [133]. Receptor activation also leads to
production of platelet- activating factor by endothelial cells which stimulate their
mitosis and migration [129]. Chemoattractant molecule production is also induced
by receptor signaling which allows for monocyte recruitments [134]. By regulating
factors involved in every step of the angiogenic process i.e. vascular cell
permeability, migration, proliferation and sprouting, VEGF acts as a potent
angiogenic factor. Proliferation of the vascular cells has been observed as early as
24 hour after the induction of hindlimb ischemia in murine models and peaks at
days 3 and 7 [135]. VEGF also works synergistically with other growth factors
which enhance angiogenic response [136]. The increase in endothelial cell mitosis
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also corresponds to morphological changes in smooth muscle cells which
represents a shift from contractile to proliferative phenotype such as appearance
of rough endoplasmic reticulum and many free ribosomes [137].
Vasculogenesis
Asahara and colleagues showed for the first time in 1997 that the cells isolated
from the blood can form new vessels thus challenging the dogma that postnatal
vascularization is operated by proliferation of pre-existing endothelial cells. They
showed that a subset of CD34+ (hematopoietic stem cell) population of cells in
peripheral blood upon culture express endothelial cell markers such as CD31 and
these cells could be incorporated into newly formed blood vessels following murine
hindlimb ischemia [45]. This new cell population was named endothelial progenitor
cells (EPCs). Further studies demonstrated the existence of more than one
endothelial cell progeny [138]. Since then other cell populations such as myeloid
cells, side populations and tissue resident stem cells have been shown to
differentiate or transdifferentiate into endothelial cells [139]. Due to the
heterogeneity of these cell populations, especially in humans, no specific marker
has been identified to describe putative EPC however, a panel of markers is
consistently used as a surrogate marker for cells displaying vascular regenerative
properties [139]. EPCs were originally defined as cells that were positive for the
hematopoietic cell marker, CD34 and the endothelial cell marker, VEGFR2, but
CD34 is not exclusive to hematopoietic stem cells. Low expression of CD34 is
observed on matured endothelial cells. The more immature hematopoietic stem
cell marker, CD133 is commonly used however, most studies use all three markers
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(VEGF,CD34,CD133) [140, 141]. The stem cell antigen-1 (Sca-1), a common
marker used to enrich hematopoietic stem cells in rodent tissues, can also be used
in conjunction with VEGFR2 to identify EPCs [142].
Following the discovery of these cells, numerous studies using different models
of ischemia were done to test the role of EPCs in promoting neovascularization,
and to the best of our knowledge all these studies have shown protective effects.
The incorporation of EPCs into new vessels is dependent on ischemia because
low incorporation rates are observed basally [143]. Moreover, under non ischemic
conditions basal levels of circulatory EPCs are maintained while a pool of the cells
are stored in the bone marrow microenvironment referred to as the stem cell niche.
These cells can then egress out of the niche following ischemia [128, 144].
Cardiovascular risk factors such as diabetes and smoking are associated with
decreased levels of circulatory EPCs whereas cardio protective factors such as
exercise and drugs that reduce the levels of blood low-density lipoprotein (e.g.
statins) increase the circulating levels [128, 139, 145]. These observations suggest
a direct effect of EPCs on cardiovascular health and an ischemia related
mechanism that increases the transmigration of these cells to sites of ischemia. A
complex coordinated response involving cytokines, chemokines and proteases are
required to enable mobilization from the bone marrow [144, 145].
Based on the observations that VEGF is involved in embryonic blood vessel growth
and angiogenesis Asahara et al. tested the hypothesis that VEGF is also involved
in post-natal vasculogenesis [146]. They showed that treatment with VEGF
increases EPC mobilization and this effect was abolished by using neutralizing
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antibodies against VEGF [147]. VEGF binds the VEGF receptor which leads to
activation of PI3K/AKT pathway and increased NO production. NO directly
activates matrix metalloproteinase 9 that cleaves membrane kit ligand into soluble
kit ligand. C-kit expressed on the surface of EPC is a receptor for soluble kit ligand.
The interaction between C-kit and its ligand allows EPC to egress from the bone
marrow [128].
Stromal-derived factor-1 (SDF-1), a stromal protein which interacts predominantly
with the chemokine receptor CXCR4, is also involved in EPC mobilization. EPCs
express CXCR4 and interaction between CXCR4+ EPC and SDF-1 maintains
EPCs in the bone marrow niche [148]. This interaction suggests that EPCs could
respond to increased circulatory SDF-1 level and vice versa. Because SDF-1 is a
transcriptional target of HIF-1α, SDF-1 levels are increased in both the target tissue
and circulation during hypoxia [117]. In addition to hypoxic tissues, matured
endothelial cells, pericytes, platelet and EPCs can express SDF-1 to induce EPC
chemotaxis [149, 150]. Both matrix metalloproteinase mediated disruption of SDF1 and EPC interactions within the stem cell niche as well as elevation of SDF-1
within the circulation are required for mobilization. Also, the extent of EPC
mobilization is directly proportional to blood SDF-1 levels suggesting that a
concentration gradient created by SDF-1 act as a chemoattractant for EPC [151].
Both SDF1 and VEGF activate the nitric oxide synthesis pathway and a synergistic
role of both factors has been observed to be involved in EPC mobilization even
though deletion of each individual factor exerts substantial effect on this process
[139].
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Since EPCs represent a rare population of bone marrow cells, chemoattraction is
of utmost importance in their mobilization and recruitment to injured blood vessels
thus, SDF1 and VEGF are potent regulators of EPC mobilization. Trials with
human patients have shown that the migratory capacity of EPCs or bone marrow
cells towards VEGF or SDF1 respectively enhances the functional improvements
of patients after stem cell therapy [152]. In addition to these factors, studies have
implicated other factors such as granulocyte-colony stimulating factor, monocytechemoattractant protein-1, erythropoietin, angiopoietin-1, lipid derived product
such as sphingosine-1-phosphate and more recently estrogen [128, 139, 144, 146]
to increase EPC mobilization. Once in the peripheral blood, EPC homing to sites
of ischemia occurs through adhesion and transmigration. The activity and
expression of matrix degrading cysteine protease, cathepsin G, is required for
tissue invasion by EPCs [144].
Arteriogenesis
Due to the importance of molecular oxygen in regulating aerobic metablic, aerobes
have evolved to have alternate pathways for blood to reach the same volume of
tissue. These set of blood vessels supplying the same volume of tissue are
referred to as collateral anastomoses. The process of remodeling already existing
collateral anastomoses into larger conductance artery is referred to as
arteriogenesis (Fig 2). The initial driving force for arteriogenesis is physical,
however, bone marrow derived cells and tissue derived factors play additional role
in this remodeling process [135, 153]. Arteriogenesis is essential because an
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increase in capillary numbers without a corresponding increase in the number of
large conductance arteries is not sufficient to ensure tissue perfusion.
Blood vessels regress if they are not constantly perfused and expand on chronic
perfusion. When the perfusion rates are high, they develop thicker vessel walls
and become highly conductant. Our circulatory system has evolved to have these
backup routes for blood flow which are not normally perfused or perfused
suboptimally under normal conditions known as anastomoses [28]. These blood
vessels serve as backup system so that during ischemia when the principle artery
is blocked, blood flow is not completely shut due to the availability of these conduit
vessels. The success of

arteriogenic process is primarily dependent on the

availability of a collateral network linking preocclusive and postocclusive circulation
[135].
Upon occlusion of an artery, the pressure in the distal part of occlusion drops
while that in the proximal site is enhanced [153]. However, if preexisting
anastomoses exist between these two sites the steep pressure gradient generated
allows for increase flow through these collaterals [135]. Increased flow through the
less perfused artery increases the fluid shear stress due to the viscous drag that
blood flow exerts on the endothelium [28]. However, this represents a relatively
weak force and cannot fully account for the total morphological changes occurring
in arteriogenesis, suggesting additional biological or physical factors are involved
in increasing the blood flow [135]. Studies have shown that endothelial cells which
are in direct contact with the blood are the first to sense this force and transduce
the mechanical stimuli into intracellular biochemical response resulting in changes
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in gene expression and vascular remodeling [135, 137, 154]. Using genetic
techniques over 40 genes have been found to have shear-stress response element
[155-157]. Through the activation of these genes, fluid shear stress is converted
into intracellular biochemical signals mediated by an array of biomolecules
including receptors, ion channel, and cytoskeletal proteins. Studies have shown
that an increase in

fluid shear stress increases bradykinin B2 GPCRs activity

[158]. Fluid shear stress can also induces cytoskeletal rearrangement, activate
integrins, and increase calcium influx through the P2X4 purinoreceptors signaling
all of which leads to endothelial cell activation [153, 159]. The transcription factor
NF-κB activated during the inflammatory phase also mediates some of these
transcriptional processes involved in arteriogenic gene expressions [160].
Collectively, these changes results in alterations in gene transcription and signal
transduction [135]. Hence, the quiescent collateral endothelium is converted into
a highly activated layer supporting infiltration and adhesion of leukocytes. Perhaps,
the

greatest

modulators

of

the

arteriogenic

responses

are

monocyte/macrophages. These monocyte/macrophages have been shown to
adhere to the luminal side of growing collaterals after coronary or femoral artery
ligation [161, 162]. Using different methods to control circulating monocyte
numbers after arterial ligation studies have shown that the number of circulating
monocytes correspond to the extent of arteriogenesis [162, 163]. Specifically the
inflammatory subsets of monocytes are responsible for arteriogenesis [47]. That
circulating monocytes play a role suggests that there are signals that allow these
circulating cells to be recruited to the site of injury. Monocyte chemoattractant
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protein 1 (MCP-1) is a chemokine whose expression is increased by fluid shear
stress. Upregulation of MCP-1 leads to monocyte/macrophage adhesion to the
endothelium and subsequent accumulation in the perivascular space [161].
Evidence for MCP-1 and its receptor CCR2 involvement in this recruitment is
provided by the observations that either knockout of MCP-1 or CCR2 attenuates
arteriogenesis through diminished monocyte recruitment [163, 164]. The migration
of monocytes is a complex process because the cells have to traverse through the
endothelial barriers. Because monocytes generate high levels of matrix
metalloproteinases and plasminogen activator, they are able to pass through the
barrier by matrix degradation [165].
In addition to these cells another leukocyte population that has been shown to
play a role in the arteriogenic process are the CD4+T lymphocytes. Using CD4+ T
lymphocyte knockout mice Stabile and colleagues showed a decreased collateral
network formation in these mice after hindlimb ischemia [48]. This decrease in
collaterals was attributed to diminished monocyte/macrophage recruitment in the
knockout mice. Furthermore, CD8+ T lymphocytes and mast cells are also known
to play a role in the arteriogenic process [135, 166].
Although the role of different cells in arteriogenesis has been elucidated the exact
contribution and the signaling pathways that are activated by each of these cell
type is currently unknown. However, the recruited monocytes/macrophages have
been reported to secrete growth factors such as VEGF and FGF, increase
vasodilatory NO production, and secretes MMPs that participate in extracellular
matrix and skeletal muscle digestion to create additional space for growing
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collaterals [153]. This vascular remodeling process is not limited to endothelial
cells but proliferation and remodeling of vascular smooth muscle cells have also
been observed. This proliferative capacity of the smooth muscle cells is mediated
by matrix metalloproteinase degradation of the basement membrane [153].
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Figure 2
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Figure 2: Mechanisms contributing to tissue revascularization after an
ischemic event: Ischemia induced VEGF production leads to mobilization of
endothelial progenitor cells (EPC) from the bone marrow into the circulation. The
circulating progenitor cells then migrate to sites of ischemic injury and form blood
island (vasculogenesis). Through further VEGF stimulation these island
differentiate to form new blood vessel (angiogenesis). Also, existing endothelial
cells can migrate and proliferate through VEGF activity to form new capillary
network (angiogenesis). In the process of arteriogenesis, the paracrine action of
monocytes leads to remodeling of preexisting anastomoses into large
conductance arteries
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Treatment strategies for PAD
Risk factor modification is important for managing PAD. Smoking cessation is
recommended for PAD patients because smoking is the single most important
modifiable risk factor. Smoking cessation improves functional performance,
reduces risk for amputation and increases survival rates in PAD patients [7, 22,
167]. Diabetes mellitus is associated with vascular abnormalities such as
endothelial dysfunction and intensive glycemic control has been demonstrated to
reduce microvascular complication. Hence, comorbid individuals are encouraged
to exercise good glycemic control [168, 169]. Supervised exercise programs are
the most effective noninvasive intervention for improving pain free walking [170].
Intermittent claudication results from inadequate oxygen supply to the limb.
Exercise has been shown to improve oxygen delivery through angiogenesis and
increase endothelial dependent vasodilation. It can also increase mitochondrial
biogenesis, reduce inflammation and ROS generation; which play key roles in the
pathophysiology of PAD [171]. These beneficial effects of exercise have been
shown to be responsible for its effectiveness in preventing intermittent claudication.
Pharmacologically two drugs, cilostazol and pentoxifylline, are approved for
treatment of PAD. Cilostazol is a quinolone derivative which inhibits type III
phosphodiesterase, and pentoxifylline is a methylxanthine derivative. Cilostazol
induces vasodilation, increase angiogenesis through peroxisome proliferatoractivated receptor-γ and cAMP pathways and suppresses apoptosis of endothelial
cells [172, 173]. Pentoxifylline, on the other hand, prevents platelet aggregation,
has anti-inflammatory properties and acts as a hemorrheologic agent [174].
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All the above treatment options are important in PAD however, chronic ischemia
and reperfusion in these PAD patients overtime culminate in critical limb ischemia
and irreversible tissue loss. CLI has an annual incidence of 500-1000/million
people and is present in 12% of the adult US population. The mortality rate is 25%
within a year of diagnosis. Morbidity is high in these individuals with about 30%
requiring amputation in the first year of diagnosis [15].
In patients with advanced PAD and critical limb ischemia, risk factor management
and treatment with pharmacological agent is not sufficient to prevent limb loss.
These patients require surgical or endovascular interventions however, majority of
these patients are not amendable to these treatment options [175]. For instance
patients with poorly controlled diabetes mellitus have lower vessel patency rates
and also present with increased rate of adverse limb events when subjected to
endovascular techniques [170]. Furthermore, in some patients the operated artery
can be re-narrowed after the initial surgical procedure leading to multiple
revascularization surgeries [12]. Likewise some patients may not be good
candidates for either percutaneous or surgical treatment due to the anatomic
distribution of the occluded arteries being so severe to permit relieve of pain or the
presence of comorbid conditions such as end-stage renal disease [25, 176]. The
later patient population represent the “no-option patient group” accounting for 30%
of CLI patients [15]. Currently, no effective treatment is available for these
individuals with amputation being the only hope for pain alleviation. In these
patients the chronic ischemia burden exceeds the capacity of the peri-ischemic
vessels to diffuse oxygen and nutrient to the organ as well as endogenous
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reparative mechanisms [177]. Recent focus of therapeutic intervention to the nooption patients has been delivery of exogenous cellular and molecular agents to
promote revascularization. Studies using

animal models have shown that

administration of HIF1-α and growth factors such as VEGF and fibroblast growth
factors (FGF) can enhance vasculogenesis, angiogenesis and arteriogenesis in
ischemic limbs, attenuate tissue injury, increase muscle regeneration and improve
limb function [117, 178-181]. These preclinical studies provided basis for clinical
trials to deliver these exogenous agents to PAD/CLI patients. Several clinical trials
have been conducted with these agents to elucidate their efficacy in patient
populations. A phase III clinical trial testing the efficacy of FGF in no-option CLI
patients showed no change in time to amputation or death between treated and
placebo groups [182, 183]. Similarly, trials using VEGF or HIF1-α showed no
change in peak walking time or maximal treadmill time respectively [184, 185].
These trials with single agents have largely been negative or resulted in no
measureable difference between groups despite promising preclinical, phase I and
in some cases phase II clinical trials [182]. Like growth factors, many animal
studies have reported a role for bone marrow derived and peripheral blood
mononuclear cells in recovery from HLI [45, 47, 48]. Several cell types such as
peripheral blood or bone marrow mononuclear cells or isolated cell population from
blood or bone marrow using selective markers have been injected and tested for
their efficacy. Over 50 clinical trials have been conducted and some are still testing
these cell therapies [175, 177]. Modest level of efficacy have been observed in
these studies with regard to end-points such as ankle brachial index, pain-free
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walking, tissue perfusion etc. Most of these clinical trials with these cells did not
yield encouraging results which could be due to the limitations in identifying the
correct dose, mode and frequency of administration of these agents [175]. It is
worth noting that significant improvement has been made over the past decade in
fine-tuning these factors. Also, the patient population in the clinical setting are
individuals with diverse cardiovascular risk factors which have been associated
with decreased circulating progenitor cell number and function. A number of
studies have reported impaired mobilization or increased senescence of
endogenous EPCs in hypertension, hypercholesterolemia, and diabetes mellitus
[186-188]. The potential effect of these risk factors on the function and activity of
exogenously administered progenitor cells was demonstrated by a study showing
that diabetic impairment in angiogenesis could be reversed if progenitor cells were
administered together with agents to promote synergism with local trophic
pathways [189]. This suggests that agents that can target multiple deleterious
pathways involved in PAD progression could be important treatment options for
PAD patients.
Project objective
Impaired tissue perfusion secondary to atherosclerosis is the underlying cause of
several adverse chronic conditions such as PAD [7]. Unabated ischemia resulting
from this atherosclerotic burden results in tissue necrosis and loss in these patients
[190]. Treatment options for these patients include use of pharmacological agents
such as cilostazol and antiplatelet therapy in early stage disease patients to relieve
pain. Endovascular or bypass surgery can be employed in advanced patients [12,
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16, 170]. Use of angiogenic agents such as VEGF, FGF and hepatocyte growth
factor have also been tested [175]. More recently autologous bone marrow or
peripheral blood cells have been tested as treatment option for these individuals
[177]. Although these treatments are currently available, their efficacy have been
marginal in part because they do not account for the complex interplay of factors
such as ROS and chronic inflammation that underline the disease condition.
Therefore, new therapies are needed that could target these multiple underlying
causes such as oxidative stress and chronic inflammation.
Revascularization after ischemia is tightly regulated by the transcription factor
HIF1-α. Activation of HIF1-α leads to the expression of angiogenic genes such as
VEGF which is essential for EPC mobilization (vasculogenesis) as well as
sprouting and migration of endothelial cells to form new thin walled vessels
(angiogenesis). HIF1-α can also regulate the arteriogenic response through its
upregulation of monocyte-chemoattractant protein-1 expression thus, HIF1-α is a
viable target for ischemic diseases [117]. HIF1-α is negatively regulated by prolyl
hydroxylases (PHDs) which are Fe2+ requiring enzymes. Therefore, strategies to
inhibit PHD using either pharmacological agents or Fe 2+ chelators have emerged
as possible treatment options for these individuals. Animal studies using PHD
inhibitors have shown protection in HLI through HIF1-α stabilization [60, 120, 180].
However, the use of these chelators and inhibitors could be toxic and HIF1-α gene
therapy for CLI patients is largely negative [185].
Recent observations have shown increased levels of reactive carbonyls in
ischemic muscles of PAD patients [191, 192]. In addition to promoting tissue injury
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directly through reaction with biomolecules these molecules affect the response
involved in revascularization. At high concentrations, lipid peroxidation products
such as 4-hydroxynonenal are reported to inhibit VEGF production [193]. Similarly
acrolein, a highly reactive lipid peroxidation product, has been reported to inhibit
EPC mobilization [142]. Moreover, high levels of oxidative stress has been shown
to induce senescence of stem/progenitor cells [177, 194]. These observations
suggest that oxidant stress may contribute in part to the defective revascularization
process observed in PAD patients and may suggest why the administration of
proangiogenic agents in the clinical setting was not effective. Thus, removal of
lipid-peroxidation products in ischemia could be another strategy to increase the
revascularization potential and attenuate tissue injury.
Carnosine is an endogenous dipeptide, comprising histidine and the nonproteinogenic amino acid β-alanine, which is synthesized by an ATP grasp domain
containing enzyme carnosine synthase (ATPGD1) [195]. Carnosine is present in
high concentration in skeletal muscle, heart and brain. It is a food constituent that
is highly abundant in chicken and beef. Studies have shown that carnosine is a
potent chelator of divalent metals such as Fe2+ and Cu2+ [196, 197]. Given the
observation that Fe2 chelators such as deferoxamine can increase HIF1-α levels
and improve recovery from HLI [198] we rationalized that carnosine can increase
revascularization in HLI through HIF1-α stabilization. Furthermore, our lab and
others have shown that carnosine can form conjugates with lipid peroxidation
products thereby limiting their reactivity [199]. Given the extensive evidence that
supports a role of lipid peroxidation product in tissue injury associated with
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ischemia and recent evidence linking their levels to diminished progenitor cell
levels and angiogenesis [142, 192], we postulated that quenching of reactive
aldehydes by carnosine could be beneficial in HLI.
In this series of investigations, we hypothesized that carnosine can promote postischemic angiogenic and arteriogenc responses through metal chelation and
aldehyde quenching. To address this hypothesis we tested the effect of oral
carnosine supplementation on revascularization after mouse HLI. We used Laser
Doppler imaging technique and microfil perfusion coupled with micro-CT analysis
to determine tissue perfusion. The effect of changes in tissue perfusion on muscle
integrity and lipid peroxidation product levels were analyzed. We examined the
role of carnosine on ischemia-induced EPC and immune cell mobilization and
recruitment. We used cell culture models to analyze the molecular pathways that
are regulated by carnosine. Results from this study shows that carnosine improves
blood flow in the ischemic limb of the HLI mice and provides the platform to start
clinical trials in PAD patients and determine whether supplementation with
carnosine can improve blood flow/ABI in these patients.
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CHAPTER II
ORAL CARNOSINE SUPPLEMENTATION PROMOTES
REVASCULARIZATION IN A MURINE HINDLIMB ISCHEMIA MODEL
Introduction
Carnosine, (β-alanyl-L-histidine), was discovered in the late 19th century by the
Russian chemist, V. Gulewitch as a non-protein nitrogen-containing compound in
meat; hence the name carnosine (from the Latin word carnis meaning meat/flesh)
[200]. Currently, about 10 variants of carnosine have been identified which are
classified into the histidyl dipeptide family [200]. All vertebrates’ tissue analyzed
have one or more derivatives of histidyl dipeptides with mammals usually
possessing carnosine and one methylated isoform i.e. either anserine or balenine,
except for humans, that have carnosine only [201]. Carnosine is highly abundant
in skeletal muscle and other excitable tissues such as heart and brain. The skeletal
muscle concentration in humans is about 20-30mmol/kg dry weight hence
carnosine is one of the top ten metabolites in the skeletal muscle [202]. Such high
concentrations in muscle suggest a critical role of this dipeptide in skeletal muscle
function thus, creating the need to understand its metabolism and function.
Carnosine is synthesized by the enzyme carnosine synthase (ATPGD1). Recent
work by Drozak, et al. characterized this enzyme as an ATP-grasp domain
containing protein [195]. The enzymatic reaction involves peptide bond formation
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between β-alanine and histidine (Fig. 3), with β-alanine being the rate limiting
substrate [203]. β-alanine is synthesized from catabolism of uracil, decarboxylation
of aspartic acid and oxidation of 3-aminopropanal [204-206]. In addition to these
endogenous synthesis, β-alanine can also be taken as a supplement to increase
tissue carnosine levels [203]. Intracellular transport of β-alanine is achieved
through TAUT and PAT-1 transporters [207].
The presence of a β-amino acid in carnosine makes it resistant to tissue
peptidases. Hydrolysis of carnosine into constituent amino acid is catalyzed by a
specific peptidase referred to as carnosinase. Carnosinase exists in two isoforms
that are present in the serum and cytosol respectively [201, 208]. The activity and
expression of these degradative enzymes vary across species with humans having
a higher serum carnosinase activity and expression than rodents [209, 210]. The
cytosolic isoform of the enzymes is highly abundant in liver, kidney and skeletal
muscle of humans and rodents [200, 207]. Regardless of the tissue distribution
cytosolic isoform has a lower activity compared with serum isoform [201].
Carnosine is transported across the plasma through the activity of a family of
proton coupled transporters (PHT1, PHT2, PEPT2, and PEPT1) [211-213].
PEPT1 is highly expressed in small intestines and plays an essential role in the
absorption of ingested carnosine into the bloodstream [213]. PEPT2 on the other
hand is expressed on the plasma membrane of several tissues such as kidney and
skeletal muscle. Studies with the PEPT2 KO mice have shown that PEPT2 is
involved in the extrusion of carnosine from the skeletal muscle and import of
carnosine to the kidney and brain [214]. However, studies by Everaert et al.
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showed that the relative expression of PEPT2 transporters in muscle is low and
PHT1 is the key transporter for carnosine in the skeletal muscle [207]. Because
these transporters are non-specific it is difficult to elucidate their contribution in
regulating intracellular carnosine levels. Although β-alanine is considered the rate
limiting substrate, histidine is also known to affect carnosine levels [203, 215].
Decarboxylation of histidine to histamine by histidine decarboxylase can affect
intracellular carnosine concentration [207]. Also, β-alanine can be transaminated
by β-alanine-2-oxoglutarate transaminase and β-alanine-pyruvate transaminase.
Inhibition of these transaminase enzymes increase carnosine levels in skeletal
muscle and cardiac tissue [216]. Carnosine can be methylated to its analogues
anserine or ophidine, decarboxylated to carcinine or acetylated to acetyl carnosine
however, these modifications are species-specific [201, 217]. Fig. 3 provides a
summary of factors regulating carnosine homeostasis in rodent muscle.
Carnosine has the ability to buffer intracellular pH, because the imidazole ring of
histidine, has a pKa close to physiological pH that imparts buffering capacity to
histidyl dipeptide. During intensive exercise lactic acid is accumulated which is
decomposed to lactate and proton that leads to decreased pH thus limiting muscle
function [217]. A direct role of carnosine in regulating proton levels was described
by Severin et al. who showed that treatment with carnosine prevents acidification
induced by lactic acid without affecting lactate accumulation thus, preserving
excitation-contraction-coupling in isolated frog muscle [217, 218]. Carnosine also
affects intracellular calcium regulation presumably through modulation of
sarcoplasmic reticulum calcium release and increases the sensitivity of contractile
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proteins to calcium [219]. Hence, both pH buffering and calcium handling
properties of carnosine are essential in regulating muscle contraction. In addition
to pH buffering carnosine is known to exhibit antioxidant properties, [220] quench
highly reactive carbonyl species [199, 221] and chelate divalent metals such as
Cu2+, Fe2+ and Zn2+ [196, 197]. Carnosine also regulates neutrophil function,
exhibits anti-aging and anti-inflammatory functions, regulates enzymes such as
phosphorylase a, modulates gene transcription and possibly translation through
regulation of eukaryotic initiation factor 4E protein [222-224].
Based on its well-characterized role in scavenging ROS, calcium regulation, metal
chelation and aldehyde quenching, we sought to elucidate a role for carnosine in
recovery from hindlimb ischemia (HLI). In these studies we used a wellcharacterized murine model of HLI to determine the therapeutic potential of
carnosine in HLI.

45

Figure 3

46

Figure 3: Schematic overview of factors regulating muscle carnosine
homeostasis in mice: Ingested carnosine can be absorbed as the intact molecule
or degraded into constituent amino acids within the intestinal lumen. Carnosine
can be transported to the myocyte through the activity of PHT1/2 transporters.
Intramuscular carnosine can be degraded, methylated or stored. On the other hand
intramuscular β-alanine transport is through TauT. In the muscle it can be used for
carnosine synthesis or transaminated for energy generation. Histidine, although
not the limiting substrate, can be decarboxylated to histamine
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Experimental Procedure
Animals and reagents: Male C57BL6J mice (16-18 weeks old) were obtained
from Jackson Laboratory (Bar harbor, ME). Mice had access to chow ad libitum
and were placed on a 12hr light/dark cycle. All protocols and procedures were
approved by the Institutional Animal Care and Use Committee of the University of
Louisville. Carnosine, hemoxylin and eosin (H&E) dyes were obtained from Sigma
Aldrich, Microfil dye from Flow Tech Inc and isolectin antibody from Molecular
Probes.
Hindlimb Ischemia Surgery (HLI): The murine hindlimb ischemia (HLI) model
used in this study involved ligation of the femoral artery and vein. The mice were
anaesthetized using 1-3% isoflurane in 100% oxygen at a flow rate of 1L/min.
Once fully anaesthetized, depilatory cream was applied to the right hindlimb to
remove excess hair and expose the skin. Betadine and 70% alcohol were applied
consecutively then a 5mm incision was made on the thigh within the femoral
triangle. The inguinal fat pad was pulled aside to expose the underlying neuro
vascular bundle. To obtain a good view of the vasculature, the membranous
femoral sheath was removed followed by ligation of the femoral artery and vein at
two points which were 2mm apart. The intervening blood vessel was excised and
the skin closed with two discontinuous sutures. Mice were allowed to recover from
the surgery. Sham operated mice were treated as described above except that the
vessels were not ligated. Regarding carnosine supplementation two different
protocols were used. In the first study mice were pre-treated with carnosine at a
concentration of 1g/L in their drinking water for 7 days and then subjected to either
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sham or HLI surgery. This study group will be referred to as pre-treated mice. The
second protocol involved

carnosine treatment after HLI surgery. Mice were

subjected to HLI and sham surgeries and immediately supplemented with
carnosine (1g/L) in drinking water throughout the recovery process. This latter
group will be referred to as post-treated study.
Laser Doppler Perfusion Imaging (LDPI): Post ischemia tissue perfusion was
monitored using Peri Scan PIM II laser Doppler device (Perimed). These analyses
were carried out on whole limb for the pre-treated group on post-operative day 14
and on the feet for the post-treated group on post-operative days 7, 14 and 21.
Mice were anesthetized as described above, placed in the supine position (for
whole limb imaging) or prone position (for feet imaging) and body temperature
maintained throughout the imaging by placing them on a heating pad set at 37oC.
Blood flow in the limbs was displayed as laser frequency changes using different
color pixels. Images were analyzed with both NIH image J and moorLDI V6 PC
analysis software. The ratio of the flow obtained for the ligated (ischemic) and
contralateral limb was reported as the percentage of tissue perfusion recovered.
Vascular Casting and Micro- Computed Tomography (microCT) analysis:
After 21 days of recovery from HLI, the post-surgery treated mice were
intraperitoneally injected with 100 µl of 100 unit/ml heparin to prevent blood
coagulation and sedated with pentobarbital. When the mice were fully sedated an
incision was made in the thoracic cavity to expose the heart. A blunted 25 gauge
needle was cannulated through the left ventricles. The mice were systemically
perfused at a constant rate of 5ml/min with the vasodilation solution (100 µM
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adenosine, 10 µM sodium nitroprusside and 0.05 wt. /vol bovine serum albumin).
Undiluted microfil vascular casting agent (Flow Tech Inc, MA) was mixed with 10%
volume of curing agent and perfused systemically until a good filling of the
vasculature was obtained. The casting was allowed to polymerize at room
temperature and the entire hindlimb limb deskinned. To obtain whole mount
images of these limbs the deskinned limbs were placed in increasing concentration
of glycerol (40%, 60%, 80% then 100%) successively for 24 hours at each
concentration. Whole mount images were obtained from these samples by imaging
with a digital CCD camera (Nikon). For microCT analyses the samples were further
processed by fixing in 10% neutral buffered saline for 18-20 hours and decalcified
with Cal EX II for 48 h. Samples were stored in 70% ethanol until imaging. MicroCT
imaging was carried out on a MicroCAT (Siemens) using following parameters;
80kVp, 200 µA and 2 x 2 binning to obtain a pixel resolution of 1024 x 1024 with
34 µM voxel sizes. Following the setup of appropriate thresholds for soft tissue
elimination, blood vessel volumes were quantified using Analyze software. Similar
to LDPI the ratio of blood vessel volumes for the ischemic and contralateral limbs
was used to assess the extent of arterial filling.
Histology: Histological analyses were conducted on formalin fixed tissues for the
hematoxylin and eosin (H&E) staining and OCT-frozen sections for isolectin
staining. For H&E staining, following euthanasia the hamstring muscles were
excised, formalin fixed and paraffin embedded. Cross sections of muscles were
made, mounted on slides and stained with hematoxylin and eosin. The muscle
cross sections were analyzed for muscle regeneration and necrosis. For isolectin

50

staining, hamstring and gastrocnemius muscles were harvested after euthanasia,
placed in cryomolds and covered fully with OCT compound. The molds were
rapidly placed in cold 2-methyl butane to freeze quickly and prevent ice crystal
formation. Cryosections were prepared and incubated with isolectin antibody
(Molecular probes) which is already conjugated with a fluorophore. For nuclear
staining the slides were counterstained with 4’,6-Diamidino-2-Phenylindole
Dilactate (DAPI). Samples were imaged using Nikon Eclipse Ti microscope and
analyzed using NIS-Element AR analysis software (Nikon).
Metabolic phenotyping: Limb function/physical activity of the HLI mice was
assessed using metabolic chambers (TSE phenomaster system; Bad Homberg
Germany). We determined mice movement (both ambulatory and fine movements)
as a measure of limb function. In addition to these parameters we also examined
their respiratory exchange ratio (RER), oxygen consumption, and whole body
energy expenditure.
Complete Blood Count Analysis: Following pentobarbital euthanasia, blood
samples were collected by cardiac puncture. The blood samples were placed on
ice for 30 mins. The samples were analyzed on Abbott cell-dyn system to obtain a
complete hematological profile of the mice.
Data analysis and statistics: All the experimental results are represented as
mean  SEM. For studies involving only two groups the unpaired student T- test
was used for analysis whereas for studies involving groups that are greater than
two one-way ANOVA was used with Bonferroni corrections. All statistical analysis
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was done with GraphPad analysis software. A p value < 0.05 was considered
significant.
Results
Limb perfusion is enhanced in the ischemic limb of carnosine treated mice:
To test the prophalytic potential of carnosine, mice were pre-treated with or without
carnosine at a concentration of 1g/L in drinking water for 7 days and subjected to
HLI surgery. Carnosine treatment was continued during the recovery process. Our
results show that tissue perfusion was significantly increased in the carnosine pretreated (63 ± 6%) compared to the non-treated (19 ± 3%) HLI mice (Fig. 4). Based
on these results we investigated the therapeutic potential of carnosine in promoting
wound healing responses. Wild type (WT) C57/BL6 mice (18 week old) were
subjected to HLI and sham surgeries. After surgeries, mice were treated with or
without carnosine (1g/L) in drinking water. Recovery of blood flow was monitored
by LDPI over a period of 21 days. No difference was observed between the nontreated and carnosine treated groups after 7 days of recovery however, 14 days
after the surgery carnosine treated mice showed a significantly higher tissue
perfusion (31.2 ± 2%) compared to non-treated mice (20.2 ± 1.42%). This
increased tissue perfusion persisted after 21 days of recovery in carnosine treated
mice (49 ± 6%) compared to (28 ± 4%) non-treated HLI mice (Fig 5). Collectively
these results show that carnosine pre-treatment or post-treatment augments
wound healing responses to increase blood flow in the ischemic limb.
Carnosine supplementation augments post ischemic arteriogenesis: Three
processes namely arteriogenesis, angiogenesis and vasculogenesis have been
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shown to account for revascularization in post-natal life. To better understand
which of these processes are responsible for promoting carnosine-mediated
revascularization we performed Microfil casting coupled with microCT analysis to
determine the vascular density and filling in the post-treated HLI mice following 21
days of recovery. Microfil casted images showed an increase in surface
vasculature in carnosine treated compared to the non-treated mice (Fig 6A).
MicroCT analysis of microfil–casted samples provides a detailed view of the entire
mouse hindlimb vasculature thereby allowing for the visualization of an extensive
tortuous network of arteriogenic collaterals and capillary network. These analyses
showed that vascular density in the carnosine treated HLI mice was significantly
enhanced compared to non-treated HLI mice (Fig 6B and C) suggesting that
supplementation of carnosine increases arteriogenesis in the ischemic limb.
Carnosine increases muscle regeneration and neovascularization: To
determine if the increase in blood flow induced by carnosine affects the
morphological changes induced by ischemia, we performed histopathological
analysis using Hematoxylin and Eosin (H&E) staining. Histological assessment of
the hamstring muscle close to the site of ligation showed an increase in muscle
regeneration after 7 days of recovery in the ischemic muscles of non-treated mice
characterized by centrally located nuclei and regular polygonal shaped myofibers.
Notably, this effect was enhanced with carnosine treatment (Fig 7). Furthermore,
staining of skeletal muscle with endothelial cell marker isolectin B4 showed that
carnosine treatment following HLI significantly increased capillary density
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compared to the non-treated HLI mice (Fig 8) suggesting that angiogenesis is
involved in carnosine-mediated revascularization.
Carnosine supplementation improves limb function in the HLI mice:
Peripheral arterial disease (PAD) is considered to be one of the leading causes of
morbidity in adults [7]. To test whether carnosine can be used as a therapeutic
intervention to increase physical activity in PAD patients, we measured the
ambulatory and fine movements of HLI mice in metabolic cages after 14 days of
recovery from surgery. Our results show that there is no change in fine movements
between the non-treated and carnosine treated HLI mice (Fig 9C). However, a
significant increase in ambulatory movement was observed in the carnosine
treated compared to the non-treated mice (Fig 9B). We observed a trend towards
an increase in total movement with carnosine treatment although this change did
not achieve statistical significance (Fig 9A). Further, we observed that VO2 was
significantly increased in carnosine treated (4050.9 ± 160.03) compared to nontreated (3278.6 ± 166.02) mice. Similarly, VCO2 was increased to 3977± 133.7 in
carnosine-treated compared to 3278.6 ± 166.02 in non-treated HLI mice (Fig 9 D
and E). No change in respiratory exchange ratio (RER) was observed. Taken
together, these results demonstrate that increase in blood flow by carnosine
treatment is concomitantly followed by restored limb function.
Complete Blood Count (CBC) analysis: To evaluate the overall health of the
mice following ischemia and carnosine treatment we performed CBC analysis after
3 days of recovery from HLI. We observed a trend towards a decrease in white
blood cells, neutrophils, monocytes, eosinophils and platelets with ischemia.
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These levels were restored to that in the sham with carnosine treatment after
ischemia (Fig 10 A-C, E, J). Lymphocyte, red blood cells, hemoglobin and
hematocrit levels however remained unchanged between the groups (Fig 10 D, F,
H, I).
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Figure 4
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B
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Figure 4: Carnosine pre-treatment improves tissue perfusion. WT C57/BL6
mice (17 week old) were pre-treated with/without carnosine for 7 days and
subjected to HLI. (A) Doppler images of control and carnosine treated mice
following 14 days of recovery from HLI. Red represents normal perfusion, blue, a
marked reduction in tissue perfusion and yellow and green represent a trend
towards restoration of normal perfusion (B) Quantification of the Doppler images.
Values are represented as a mean for n=5 mice in each group. *P<0.01 vs nontreated mice.
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Figure 5
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Figure 5: Post-surgery carnosine treatment improves tissue perfusion: (A)
Representative laser Doppler perfusion images monitoring foot perfusions on postoperative days 7, 14 and 21 in control and carnosine treated WT C57/BL6 mice.
Region of interest is indicated by the red boxes (B) Quantification of foot perfusion
rates expressed as percentage of blood flow in the ischemic limb to the
contralateral limb. n= 5-9. *p<0.01 vs control mice
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Figure 6
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Figure 6: Whole mount images and microcomputed tomography (micro-CT)
angiograms

demonstrating

that

carnosine

treatment

increases

arteriogenesis. WT C57/BL6 mice subjected to HLI were allowed to recover for
21 days with or without carnosine supplementation. (A) Representative whole
mount images of carnosine treated and non-treated glycerol clarified microfil
perfused limbs. Results shows increased microfil filling (increase yellow coloration)
in ischemic limbs of carnosine-treated compared with non-treated mice.

(B)

Representative images of micro-CT scans demonstrating increased vascular
growth in carnosine treated compared with non-treated mice. Arrows indicate
proximal ligation sites. (C) Quantification, represented as a percentage of vascular
density of ligated limb to contralateral limb. n=10 mice in each group. *p<0.01 vs
control mice.
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Figure 7
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Figure 7: Carnosine treatment increases muscle regeneration and attenuates
ischemic tissue injury: H&E staining of paraffin embedded sections of the
hamstring muscle captured under bright field conditions with 10X objective. (A)
Representative images for non-treated and carnosine treated mice after 7 days of
recovery from HLI surgery. Contralateral limbs are included for comparison. (B)
Data expressed as mean  SEM for the number of regenerated myocyte (myocytes
with centrally located nuclei) from 4-5 fields per section (4-5 sections/mouse). n=5
for each treatment. *p<0.01 compared to non- treated HLI mice.
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Figure 8
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Figure 8: Neovascularization is increased with carnosine treatment: (A)
Isolectin B4 staining of ischemic and contralateral hamstring muscles of nontreated and carnosine-treated HLI mice following 21 days of recovery (B)
Quantitative analysis of capillary density. n=5 for each treatment. *p<0.05 vs nontreated ischemic limb. # p<0.05 vs non-treated contralateral limb.
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Figure 9: Physical activity and metabolic rate is increased in carnosine
treated mice. Measurements of (A) total movement, (B) ambulatory movement
and (C) fine movement of carnosine treated and non-treated mice after 14 days of
recovery from HLI were used to assess the physical activity. Metabolic state
assessment was done by examining, (D) VO2, (E) VCO2 and (F) respiratory
exchange ratios (RER) in the treated and non-treated HLI mice.

Data are

presented as mean  SEM of n=5 mice in each group. *p<0.05 vs non-treated mice
(control).
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Figure 10: Blood cells populations and properties are not affected by
carnosine treatment. Complete Blood Count of (A) white blood cells and the
subpopulations of white blood cells i.e. neutrophils, monocytes, lymphocytes,
eosinophils (B-E,G) in peripheral blood were determined along with (F) Red blood
cells, (H) hemoglobin, (I) hematocrit, (J) platelets levels. All measurements were
taken following 3 days of recovery from surgery. No changes were observed in
any of these blood cell populations.
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Discussion
The results from this study show that carnosine increases blood flow in the
ischemic limb by promoting post-ischemic angiogenic and arteriogenic response.
Our results demonstrate that carnosine supplementation increases arterial
volume/diameter, capillary density and muscle regeneration in the HLI mice
compared with non-treated HLI mice. Furthermore, limb function was significantly
improved in the carnosine treated HLI mice.
A major goal of this study was to evaluate the therapeutic potential of carnosine in
critical limb ischemia. This is particularly important because of the high rates of
mortality and morbidity in these individuals [15]. The model of murine HLI
employed in this study is important in evaluating changes induced in critical limb
ischemia and monitor efficacy of possible candidate drugs [175]. Ligation of
femoral artery is reflective of the human disease in which occlusion of the femoral
artery is frequently observed [12, 225].
Laser Doppler Perfusion Imaging (LDPI) provides noninvasive recording of
microvascular tissue perfusion allowing for longitudinal assessment of blood flow
after occlusion [226]. Our results show that pre-treatment of carnosine in mice
significantly increased tissue perfusion in the HLI mice compared to non-treated
mice. Furthermore, our results showing that carnosine supplementation improves
blood flow after HLI surgery suggests that carnosine can be used as therapeutic
intervention for PAD patients. We did not observe any toxic effects within the doses
that were used in this study although symptoms of paresthesia are observed in
humans with single doses higher than 800 mg [227].
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One of the limitations of LDPI is the limited depth of penetration thus, only surface
vascular perfusion can be monitored. The femoral artery is fairly superficial to be
monitored by LDPI, however, the femoral artery serves as a conduit for other
vessels and its occlusion disrupts flow to the entire limb. Therefore, it is important
to monitor developing collateral networks and arterioles deep within the muscle to
evaluate the extent of damage and recovery. Microfil-perfusion coupled with
microCT imaging, offers a more holistic assessment for evaluating vascular
remodeling. This silicon-based radio-opaque agent once injected through the left
ventricles form a 3-D cast of the vasculature. The mineral phase of bone, due to
its radio-opaque nature, can interfere with micro-CT analysis. Therefore, formic
acid decalcification is used to remove the mineral phase of bone without affecting
the already casted vasculature [228]. With additional threshold settings to eliminate
soft tissue extensive network of tortuous arterioles can be observed, which a
hallmark of arteriogenesis is. Our results show an increase in the appearance of
tortuous vessels with carnosine treatment. We also observed a significant increase
in the arteriolar filling with carnosine treatment by using Analyze software. This
technique cannot adequately quantify capillary density due to its low resolution and
detection limits. Therefore, it is primarily used to quantify the extent of
arteriogenesis thus, suggesting that carnosine treatment increases arteriogenesis
in HLI mice.
Angiogenesis is an important contributor to post-ischemic revascularization. Due
to the limitation of microfil-perfusion in measuring capillary density, we used
isolectin staining to determine the role of carnosine in angiogenesis. Isolectin
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staining was significantly more in carnosine treated ischemic hamstring muscle
following 3 weeks of recovery compared to non-treated mice. Interestingly, no
difference was observed between the contralateral limb and ischemic limbs of nontreated mice. Collectively, our results demonstrated that carnosine treatment
increases both angiogenesis and arteriogenesis in HLI mice.
Excessive myofiber damage has been observed in the gastrocnemius muscle of
peripheral artery disease patients [192]. We evaluated the effect of carnosine on
ischemia induced tissue injury. After 7 days of recovery from ischemia we
observed an increase in the number of regenerated muscle in the ischemic muscle
of carnosine treated compared with non-treated mice. This effect was sustained at
14 days of recovery and tissue injury significantly reduced at this time point (data
not shown). To further determine whether the recovery of tissue perfusion and
restoration of muscle structure improves limb function we determined physical
activity by monitoring their movement in a metabolic cage. These results showed
that physical activity of carnosine treated mice was significantly improved
compared to non-treated mice. Although, metabolic cage analysis provided
sufficient evidence for limb function, treadmill exercise can be employed in future
to evaluate stress-induced influences in limb function.
In conclusion, despite the great utility of the murine HLI model some limitations
exist. Firstly, in PAD the underlying cause is atherosclerosis while in this model
obstruction is achieved surgically. Also, the clinical patients present with several
other cardiovascular risk factors such as diabetes which is associated with
microvascular dysfunction. Future investigations examining the role of carnosine
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in the presence of one or more of these risk factors may be important to further
evaluate the use of carnosine for the patient population.
In summary our results provides the first evidence that carnosine improves wound
healing after HLI. Our results show that carnosine can regulate arteriogenesis,
angiogenesis and attenuate tissue injury. These results demonstrate the potential
therapeutic utility of carnosine. However, further studies are needed to evaluate
the optimal dose, frequency of dose and best mode of administration for the PAD
patients.
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CHAPTER III
CARNOSINE IMPROVES REVASCULARIZATION BY AUGMENTING THE POSTISCHEMIC ANGIOGENIC RESPONSE
Introduction
Peripheral artery disease refers to atherosclerotic narrowing or blockage of arteries
that supply blood to the limb. Risk factors include smoking, diabetes, ageing,
hypertension, dyslipidemia and obesity and modification of these risk factors
represent a viable option in the management of PAD [7, 170].
Carnosine levels have been shown to be negatively associated with some of these
risk factors while its supplementation is essential in modifying these risk factors.
For instance in apolipoprotein E null mice, which are highly susceptible for
developing atherosclerosis, carnosine was effective in preventing the development
of atherosclerosis [229]. A decrease in carnosine levels have been observed in
Type II diabetic humans [230]. In animal models of obesity, improved insulin
sensitivity and reduced cardiovascular risk factors such as dyslipidemia and
hypertension have been demonstrated with carnosine treatment [231-233]. Ageing
in humans is also associated with a decrease in muscle carnosine content [234].
Interestingly exercise, an important non-invasive option for improving intermittent
claudication and rest pain is associated with an increase in muscle carnosine
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levels [235, 236]. These observations suggest a role of carnosine in vascular
health and therefore a viable candidate to investigate.
In diverse models of ischemia carnosine has been observed to play a protective role.
Intraperitoneal administration of carnosine at a concentration of 100mg/kg attenuates
ischemic injury induced by cerebral ischemia [237]. Similarly, carnosine treatment
promotes recovery of cardiac function in isolated heart model of ischemia/ reperfusion
[199, 238]. Likewise, intraperitoneal administration of carnosine protected hearts from
Adriamycin-induced cardiotoxicity and restored cardiac function after ischemia [239].
Similar effects have been observed in hepatic, renal and testicular models of ischemia
with carnosine treatment [240-244].
The protective effects of carnosine are mostly attributed to quenching of reactive
aldehydes by carnosine [245]. This property of carnosine is particularly important
because under ischemic conditions generation of reactive aldehydes is increased
and

pathways that remove these aldehyde are overwhelmed thus, carnosine

supplementation is essential to compensate for this deficit [33]. Studies with cerebral
model of

ischemia have

shown

that carnosine

supplementation

imparts

neuroprotection by improving mitochondrial function and diminishing autophagy
[246].

Inhibitory effects of carnosine on mast cell degranulation and histamine

release was reported in in-vitro models of ischemia [247]. Vasodilatory effects and
regulation of myocyte contractility through modulation of calcium homeostasis are
likely to contribute to anti-ischemic effects of carnosine.
Although the anti-ischemic effects of carnosine are known, its regulation on the
vascular adaptations to ischemia has not been studied. The mouse hindlimb ischemia
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represents a good model to study vascular adaptions to ischemia and explore the
effects of therapeutic candidates on this process. In this model the role of various
players such as inflammatory cells, cytokines and progenitor/stem cells can be
monitored in a temporal fashion to determine their possible causal role in the recovery
process.

In this series of investigations we examined the effect of carnosine

supplementation on post-ischemic angiogenic/vasculogenic response. Using flow
cytometric analysis we evaluated ischemia induced mobilization of endothelial
progenitor and immune cells to establish a role for carnosine in the regulation of these
factors. We also determined whether carbonyl quenching by carnosine can be a
potential contributor to the vascular and tissue adaptations in HLI mice.
Experimental Procedure
Material: Tyrosine–Histidine, anserine (Bachem), protease inhibitor cocktail, bovine
serum albumin, nonafluoropentanoic acid and heptaflurobutyric acid (Sigma-Aldrich),
fibrous tissue RNA isolation kit (Qiagen), VEGF (Santa-Cruz), anti-carnosine
(Abcam), anti-4-hydroxynonenal (Cosmo Bio), avian virus reverse transcriptase,
deoxy nucleotide triphosphate mix (Promega), primers (IDT), SYBR green (VWR),
Pierce ECL plus (Thermo Fischer).
Liquid chromatography / Mass spectrometry (LC/MS/MS) analysis of histidyl
dipeptides: Hamstring muscles were homogenized in a lysis buffer; phosphate
buffered saline, protease inhibitor cocktail and 200µM Tyr-His (internal standard; IS).
The homogenates were sonicated and centrifuged at 16000 g. Following
centrifugation, the supernatant was de-proteinated with 70% perchloric acid and
centrifuged again. The resulting supernatant was neutralized with 750 mM
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ammonium hydrochloride and diluted 1:1 with the mobile phase (90% water: 10%
acetonitrile and 0.1% heptaflurobutyric acid). Samples were injected onto HP 1100
LC and separated on a Polar RP column. Histidyl dipeptides (carnosine and anserine)
were detected by using Micromass Quattro LC/MS/MS system [216]. The data for
histidyl dipeptides were

acquired

by

monitoring the following transitions

226.95110.22 (carnosine); 241.1109.2 (anserine); 319 110.22 (Tyr-His). The
peptides were quantified using the peak area ratio of histidyl-dipeptide and internal
standard. MassLynx mass spectrometry software from Waters was used for the
analysis.
qRT-PCR analysis: Following euthanasia hamstring muscle of mice were harvested
and pulverized. Total RNA was obtained using Qiagen Fibrous Tissue RNA isolation
kit. RNA quantification and quality were obtained by taking ratio of the absorbance at
260nm to 280nm using Nanodrop 1000A spectrophotometer (Thermo). To synthesize
cDNA the isolated RNA and oligo dT primer mixture were heated at 70 OC for 5 mins
to allow the primers anneal with mRNA templates. dNTP’s and reverse transcriptase
(avian virus reverse transcriptase from Promega) enzymes were added to the mixture
and the resulting mixture was incubated at 42OC for 1 h followed by heating at 94OC
for 5 min to denature the enzyme. Relative gene expression was analyzed by using
cDNA, SYBR green and a pair of forward and reverse primers. The cycling conditions
include; 5 min at 95OC, 45 cycles of 10 seconds at 95 O C, 20 sec at 60 O C and 25
sec at 72

O

C . Ct values were obtained in triplicates.

Hypoxanthine- guanine

phosphoribosyl transferase 1 (HPRT1) was used as internal control gene.
Measurements were made on Prism 7900 HT (Applied Biosystem). Fold changes in
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mRNA expression between the groups were calculated according to the comparative
Ct method that involves comparing the Ct values of the gene of interest and the
internal control.
Flow cytometry: To identify the role of leukocytes and endothelial progenitor cells
(EPC’s) in carnosine

mediated recovery from HLI, flow cytometry analysis of

peripheral blood, bone marrow and skeletal muscle from HLI and sham operated
mice were carried out on BD LSR II flow cytometer. Mice were allowed to recover for
3 days. Following euthanasia blood was collected by cardiac puncture, and the femur,
tibia and muscles (hamstring and gastrocnemius) were dissected. Blood samples
were lysed, blocked by Fc and washed with 1% bovine serum albumin in PBS. The
samples were stained for leukocyte markers using a cocktail of the following
antibodies, CCR2, CD11b, F4/80, Gr-1, Ly6C, 7/4, CD19, CD4 and CD8. Samples
were stained with antibody cocktail for 30 mins, washed with BSA-PBS. For EPC’s
identification samples were treated in the same way except stained with Flk-1+ and
Sca1+ antibodies.
For bone marrow analysis, femur and tibia from both the ischemic and contralateral
limbs were flushed with Hank’s balanced salt solution (HBSS) to obtain the bone
marrow. The bone marrow was separated by ficoll and the buffy coat was washed
with 1% bovine serum albumin in PBS. Samples were blocked by Fc and stained for
EPC and leukocyte markers respectively and analyzed by LSR.
To determine the leukocyte infiltration, the hamstring and gastrocnemius muscle of
ischemic and contralateral limbs were minced in HBSS and digested in 0.2% Type II
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collagenase at 37OC for 1h. The digested tissues were passed through a 50 micron
cell strained, washed with 1% BSA in PBS, Fc blocked and stained for leukocytes.
Western blot analysis: Tissue lysates were prepared in RIPA buffer (20mM TrisHCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% NP-40). Protein samples
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE), transferred onto polyvinylidene difluoride (PVDF) membrane and blocked
with 5% milk in Tris buffered saline (TBS) with 1%-3% Tween 20. The blots were
incubated in primary antibodies at 4OC for overnight followed by secondary antibody
incubation at room temperature for 1h. Horseradish peroxidase (HRP) conjugated
secondary antibodies were used in all analysis. Membranes were developed using
HRP substrate (ECL plus form Pierce) and scanned with Typhoon bioimager (GE
healthcare)
LC/MS/MS analysis of carnosine-aldehyde conjugates: To evaluate the extrusion
of carnosine-aldehyde conjugates in urine, mice were placed on 3% glucose and
0.125% saccharin solution (1g /L). Urine was collected at different time intervals (1,
2, 3 and 12 h) after the supplementation to determine baseline conjugates levels.
Post-surgery changes in urinary conjugates were determined by collecting urine 1, 2,
3, and 12 h after the HLI surgery. The urine samples were centrifuged at 16000 g for
10 min to remove debris and spiked with 30 µl of 1mM Tyr-His (internal standard) per
500 µL of urine. The urine samples were deproteinated by centrifuged at 16000 g for
30 mins in a 3000 Da cut off filter. The filtrates were separated on HP 1100 LC
connected to a Polar RP column using 5mM nonafluoropentanoic acid (NFPA) as the
mobile phase. Detection of the carnosine aldehyde conjugates and their reduced
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forms was done on a Micromass Quattro LC/MS/MS system [199]. The ratio of peak
intensity of conjugates and the internal standard was used for quantification.
MassLynx mass spectrometry software was used for analysis.
Results
Carnosine transport to the ischemic limb is increased with carnosine
supplementation: Based on the observations that limb perfusion and function are
increased with carnosine treatment, we next analyzed carnosine levels in the skeletal
muscle of carnosine treated and non-treated HLI as well as sham-operated mice.
LC/MS/MS analysis of the hamstring muscle showed that carnosine levels were
significantly increased in the carnosine treated HLI compared to the sham and nontreated HLI mice (Fig. 11A). Surprisingly, no changes in carnosine levels were
observed in the carnosine treated sham mice suggesting that carnosine transport is
increased in the ischemic limb only (Fig 11A). To determine the factors responsible
for increase in intra- muscular carnosine levels, we determined the expression of
enzymes and transporters involved in maintaining homeostasis of endogenous
carnosine levels. We determined the expression of transporters (PHT1, PEPT1,
PEPT2, TauT), and enzymes (ATPGD1 and CNDP2). No differences were observed
in the mRNA levels of ATPGD1 and CNDP2 suggesting that there is no change in
the synthesis and degradation of carnosine by HLI surgery and carnosine treatment.
However, the expression of carnosine and dipeptide transporters PEPT2 and PHT1
were significantly increased in carnosine-treated HLI compared with non- treated HLI
mice suggesting that the increased expression of transporters may be responsible for
the increased carnosine levels in the ischemic tissue (Fig. 11B).
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Carnosine treatment increases EPC’s mobilization: Numerous studies have
shown that EPCs are mobilized from bone marrow to the site of ischemic injury to
increase post-natal vasculogenesis and angiogenesis [128]. Because, we observed
an increase in capillary density in the ischemic muscle of carnosine treated mice, we
tested whether carnosine improves angiogenesis by increasing EPCs mobilization
from the bone marrow to the site of injury. We determined EPCs levels in the
peripheral blood and bone marrow using stem/progenitor cell marker Sca-1 and the
endothelial cell marker Flk-1 (VEGFR2). Our results show that following 3 days of
recovery from HLI there was no change in the circulating EPCs levels between the
HLI and sham treated animals, however, a significant increase in EPCs mobilization
was observed in the carnosine treated HLI mice (Fig. 12E). No change in EPCs
mobilization was observed in the sham operated carnosine treated mice (Fig. 12E).
No change was observed in the bone marrow EPCs following 3 days of recovery from
HLI (Fig. 12 F). However, after 7 days of recovery EPC levels were significantly
increased in the peripheral blood of HLI compared with sham operated mice. This
increase was further enhanced in the carnosine treated mice (Fig. 12 G). Levels of
EPC in the bone marrow of both non-treated and carnosine treated HLI mice were
decreased compared to sham operated mice (Fig. 12H).
Carnosine treatment does not affect the inflammatory response induced by
ischemia: In addition to EPC’s, bone marrow derived mononuclear cells have been
shown to regulate neovascularization and collateral growth. We therefore examined
whether the levels of macrophages (CD11b+, F4/80+), monocytes (CD11b+, F4/80- ),
inflammatory monocyte subset (Ly6Chi, 7/4hi), resident monocyte subset (Ly6Clo,
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7/4lo) B cells (CD19+), CD4+ and CD8+ lymphocyte levels were changed in the blood,
bone marrow and skeletal muscle (NB. lymphocytes were evaluated in blood samples
only and macrophages in the muscle samples only). The gating strategies are
summarized in (Fig.13). All analyses were done after post-ischemia (3 days). Our
results show that the levels of bone marrow inflammatory monocytes were increased
in the HLI carnosine treated and non- treated mice (Fig. 14E), but no change in the
total and resident monocyte populations (Fig. 14 D, F) were observed. In the
peripheral blood no change was observed in the monocytic populations with HLI or
carnosine treatment (Fig. 14 A-C). Analysis of the skeletal muscle showed that
monocytes and macrophages levels were increased by HLI however, carnosine
supplementation had no additive effect on these cells (Fig. 15A-D). In addition to flow
cytometry results, qRT-PCR analysis of the monocyte chemo-attractant molecule
(MCP-1/CCL2) and its receptor CCR2 showed MCP-1 and CCR2 expression were
increased by HLI however, carnosine treatment had no additive effect (Fig. 15 E-F).
We also examined the mRNA levels of cytokines as well as cytokine regulated
effector molecules which affect the inflammatory response such as VCAM, Tie2,
TNFα, Angiopoietin, and IL-6. None of these factors were changed by HLI or
carnosine treatment (Fig. 15G). Collectively, these results demonstrate that
carnosine treatment does not affect immune cell populations and inflammatory
process induced by ischemia.
Carnosine treatment increases VEGF levels in ischemic muscle: Based on our
observations that EPC mobilization is increased by carnosine supplementation and
previous studies showing that vascular endothelial growth factor (VEGF) regulates
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EPC’s mobilization we determined VEGF levels in the ischemic muscle of the nontreated and treated mice. VEGF mRNA (Fig. 16A) and protein expression (Fig 16. C,
D) were significantly increased in the carnosine treated mice compared to the nontreated HLI mice suggesting that increase in VEGF levels may be involved in
increasing EPC mobilization. No change in VEGFR2 expression was observed.
These results suggest that the carnosine treatment increases VEGF levels in the
skeletal muscle which concomitantly increases EPC mobilization.
Carnosine treatment increases extrusion of reactive aldehyde and protein
carnosinylation: Several studies have shown that generation of reactive aldehydes
is increased in the ischemic muscle of HLI mice and PAD patients [191, 192]. Studies
from our lab and others have shown that carnosine has the ability to react with
aldehydes and can also bind with the protein-aldehyde adducts to generate
carnosinylated protein adduct [199]. We therefore determined whether carnosine
supplementation alone can increase the urinary extrusion of carnosine-reactive
aldehydes conjugates.

LC/MS/MS analysis showed that carnosine treatment

increased the extrusion of carnosine-propanal (carnosine-acrolein) conjugates
compared with non-treated mice (Fig. 17 A). The extrusion of carnosine-propanal
conjugates was significantly increased after HLI surgery compared to the baseline.
Notably, the extrusion of carnosine-propanal conjugates was significantly increased
by carnosine treatment in HLI mice (Fig 17 A). Western blot analysis of the ischemic
and contralateral tissues showed that generation of 4-HNE protein adduct was
increased in the ischemic tissue and carnosine treatment decreased the generation
of these adducts (Fig 18 A, C). Similarly, generation of carnosinylated protein
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adducts, which prevents the propagation of the free radical chain reaction initiated by
these reactive aldehydes, was increased in the ischemic muscle of non-treated HLI
mice and supplementation of carnosine enhanced carnosinylated protein adduct
generation (Fig 18 B, D). These results suggest that aldehyde quenching by
carnosine could also contribute to wound healing responses mediated by carnosine.
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Figure 11: Oral administration of carnosine increases carnosine levels in the
ischemic muscle. (A) LC/MS/MS analysis of carnosine in the hamstring muscle
of non-treated and carnosine-treated HLI mice. Treated and non-treated sham
operated mice were used for comparison. (B) qRT-PCR analysis of the different
enzymes and transporters that regulate carnosine levels. *p< 0.05 non-treated HLI
mice, # p < 0.05 vs non-treated sham and $p<0.05 vs carnosine-treated sham.
n=5
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Figure 12: Carnosine increases EPCs mobilization. EPCs were identified as a
subpopulation of the live lymphocytic cells that were double positive for Flk-1 and Sca-1.
Representative dot blot of Flk-1+/Sca-1+cells in peripheral blood after 3 days of (A) Sham
(B) Sham + carnosine (C) HLI and (D) HLI + carnosine treatment. Flk+/Sca+ cells in (E)
blood and (F) bone marrow after 3 days of recovery. (G and H) represents EPC levels in
blood and bone marrow respectively after 7 days of recovery. *p< 0.05 non-treated HLI
mice, # p < 0.05 vs non-treated sham and $p<0.05 vs carnosine-treated sham. n= 5-10 for
each group.
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Figure 13
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Figure 13: Gating strategy for evaluating immune cell regulation after HLI: To
evaluate the effect of carnosine treatment and ischemia on the immune cell
populations we employed the following gating strategy (A) Cells identified as Gr1+ were defined as granulocytes and therefore excluded from further analysis. (B)
Monocytes were identified by using CD11b+ and Ly6C+ antibodies. (C)
Inflammatory subset of monocytes was identified as high for both Ly6C and 7/4
(hereby referred to as Ly6Chi). The resident monocytes are low for both Ly6C and
7/4 (referred to as Ly6Clo). To identify the lymphocytic subpopulations we (D)
classified the cells that were neither monocyte nor granulocyte gate as
lymphocytes. (E) B-lymphocytes were identified as the subset of the lymphocytes
that are positive for CD19. (F) The remaining cells were identified as being CD4+
or CD8+.
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Figure 14: HLI increased inflammatory monocyte population in the bone
marrow. Flow cytometry analysis of (A-C) blood monocyte subpopulation and (DF) bone marrow monocyte subpopulations following 3 days of recovery from HLI.
Inflammatory and resident monocytes results are expressed as percentage of total
monocytes that were either Ly6Chi or Ly6Clo. Data is presented meanSEM,
#p<0.05 vs non-treated sham and $p<0.05 vs carnosine-treated sham, n=6-10 in
each group.
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Figure 15: HLI increases the inflammatory response in the skeletal muscle:
Flow cytometry analysis of the skeletal muscle showing recruitment of (A)
macrophages (B) monocytes (C) inflammatory monocytes and (D) resident
monocyte in the ischemic muscles. (E, F) qRT-PCR analysis for the expression of
the monocyte-chemoattractant protein -1 (MCP-1) and its receptor CCR2. (G)
Represents qRT-PCR analysis of various inflammatory cytokines in the hamstring
muscle. Data is presented as mean  SEM, #p<0.05 vs non-treated contralateral
limb and $p<0.05 vs carnosine-treated contralateral limb, n=5 in each group.
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Figure 16
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Figure 16: Carnosine treatment increases VEGF expression in the ischemic
muscle. (A) VEGF mRNA and (B) VEGFR2 mRNA expression in the ischemic and
contralateral muscles after 3 days of ischemia (C) VEGF protein levels in
contralateral and ischemic muscle of carnosine treated and control mice. (D) Data
is presented as mean  SEM. VEGF expression normalized to tubulin. # p < 0.05
vs non-treated contralateral limb. n=5 mice in each group.
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Figure 17
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Figure 17: Quenching of reactive aldehydes is increased with carnosine
treatment. LC/MS/MS analysis of pre- and post-surgery urinary metabolite levels
(A) carnosine-propanal and (B) carnosine-propanol. *p< 0.05 non-treated HLI
mice, # p < 0.05 vs non-treated sham and $p<0.05 vs carnosine-treated sham.
n=4.
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Figure 18: Carnosine treatment decreases 4-HNE protein adducts formation
and increases protein-carnosinylation. (A) Western blots images of 4-HNE
protein adducts and (B) carnosinylated proteins adducts in ischemic and
contralateral muscle following 21 days of recovery from HLI. Blots were developed
using anti-HNE and anti-carnosine antibodies (C) Represents the analysis of 4
HNE protein adduct and (D) carnosinylated protein adducts, data is presented as
mean  SEM # p< 0.01 vs contralateral and *p<0.01 vs HLI n=5 mice in each
group.
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Discussion
The results from this study show that carnosine treatment results in increased
circulating EPC. This suggests a role for neovascularization in carnosine mediated
revascularization. Cytokine analysis showed that monocyte chemoattractant protein1 and its receptor CCR2 were increased by HLI however, no additive effect was
observed with carnosine treatment. Angiogenic growth factor VEGF was significantly
increased in carnosine treated HLI mice suggesting a possible VEGF dependent
mechanism involved in EPC mobilization. We observed no changes in carnosine
transporter

and

enzyme

expression

with

ischemia

although

carnosine

supplementation under ischemic conditions increased PHT1 transporter expression.
4-HNE protein adducts were significantly depleted and the extrusion of carnosinepropanal conjugates was increased in carnosine treated HLI mice.
In our investigation we found that after 3 days of recovery from HLI surgery levels of
circulating EPCs in carnosine pre-treated mice was significantly increased compared
to non-treated mice whereas EPC levels were significantly mobilized after 7 days in
the carnosine post-treated mice. These results suggest that carnosine enhances the
adaptive response to ischemia which is essential because, a timely robust
revascularization response after an ischemic insult is necessary to prevent further
damage to the tissue. Analysis of bone marrow EPC levels from ischemic limb
showed diminished levels in both treated and non-treated tissue after 7 days of
recovery suggesting that the observed circulatory EPC levels may be coming from
the bone marrow. However, it is possible that hypoxia could affect EPC survival in
bone marrow niche. Future experiments using labelled
101

bone marrow may be

essential to delineate these pathways. These studies will be critical to define the effect
of carnosine on mobilization, survival, proliferation and homing of progenitor cells.
Surprisingly, carnosine treatment did not increase circulating EPC levels in the sham
operated mice suggesting an ischemia mediated regulatory effect on carnosine
metabolism.
Ischemic injury activates the innate immune response leading to upregulation of
cytokines and chemokines in the injured tissue. Monocyte chemoattractant protein
(MCP-1/CCL2) that binds to the receptor C-C chemokine receptor type 2 (CCR2) is
a potent chemokine for monocytes/macrophages. These monocytes/macrophages
contribute to the initiation and resolution of inflammation and revascularization.
Message levels of MCP-1 and CCR2 were increased in both carnosine treated and
non-treated HLI mice. Recent data has shown that the inflammatory subset of
monocytes (Ly6Chi) is involved in the recovery process. We examined monocyte
levels in bone marrow, peripheral blood and the skeletal muscle. Our results show
ischemia induced increases in the levels of inflammatory monocytes in both bone
marrow and adductor muscle however, carnosine treatment exerted no additional
effects. Other cytokines such as VCAM-1, TNF-α, IL-6 and angiopoietin-1 which are
known to play critical roles in inflammation were not affected by carnosine treatment.
Inflammation is like a double edge sword that can enhance revascularization but
excessive inflammation can increase oxidative stress, myocyte apoptosis and tissue
fibrosis [248]. Hence, that carnosine did not obliterate or augment the inflammatory
response may be essential to ensure reparative processes without initiating
detrimental effects of inflammation.
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Based on our results that EPCs levels are increased in carnosine treated HLI mice,
we next investigated carnosine metabolism in the HLI mice. No differences were
observed in the carnosine levels and transporters between the sham and the HLI
mice. However, levels of carnosine were significantly increased in carnosine treated
HLI mice. Similarly, expression of carnosine transporters PHT1 and PEPT2 was
increased in ischemic muscle of carnosine treated mice. Because these transporters
are pH sensitive our results suggest that the change in pH by ischemia and the
increase in carnosine levels may increase the transporter expression.
Several studies have demonstrated that VEGF is a potent inducer of EPC
mobilization [147]. To determine whether the increase in EPC mobilization in
carnosine treated mice is due to increased VEGF generation we next determined
mRNA and protein levels of VEGF in ischemic hamstring muscle. Our results show
that VEGF mRNA and protein levels were significantly increased in the carnosine
treated mice compared to the non- treated HLI mice suggesting that the increase in
muscle carnosine by carnosine supplementation may be involved in regulating VEGF
levels. VEGF is known to regulate endothelial cell sprouting and new vessel
formation, thus the increase in VEGF levels by carnosine supplementation may be
involved in increasing the capillary density through a combination of angiogenesis
and vasculogenesis.
Numerous studies have shown that generation of reactive carbonyls is increased in
the gastrocnemius of PAD patients and murine models of HLI [192]. Since carnosine
quenches reactive carbonyl we analyzed the levels of HNE adducts in the HLI mice.
Our results shown that levels of 4-HNE protein adducts were increased with ischemia
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and the generation of these adducts was significantly reduced in the carnosine
treated HLI mice. Previous studies from our lab had shown that conjugates of
carnosine-propanal forms adduct with cardiac proteins and accumulation of these
carnosinylated proteins adducts is increased in ischemic aldose reductase-null hearts
[199]. We therefore explored further whether carnosinylated proteins are increased
by carnosine supplementation. Our results show that levels of carnosinylated protein
adducts was significantly increased in the ischemic limb of the carnosine treated mice
suggesting that the capping of aldehyde protein adducts by carnosine may prevent
generation of high molecular weight adducts. Furthermore, we also observed that the
extrusion of carnosine-acrolein conjugates was significantly increased by carnosine
supplementation suggesting that the increased extrusion of reactive aldehydes by
carnosine may attenuate ischemic injury by diminishing carbonyl stress.
Collectively, we demonstrate that carnosine supplementation increases EPC
mobilization, VEGF expression and aldehyde quenching in the HLI mice
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CHAPTER IV
MECHANISMS UNDERLYING CARNOSINE MEDIATED REVASCULARIZATION.
Introduction
Timely reperfusion is critical in attenuating tissue injury from critical limb ischemia,
myocardial infarction or cerebrovascular ischemia. Vasculogenesis, angiogenesis
and collateral artery growth account for revascularization after vascular damage to
ensure tissue reperfusion. Our results show that carnosine level is increased in mice
that were supplemented with carnosine after HLI surgery. This increase was
associated with increased neovascularization, collateral artery growth, reduced
muscle damage and improved limb function. Further we observed that mobilization
of EPC is increased by carnosine supplementation.
Previous studies have shown that levels of circulating stem/progenitor cells depend
on their ability to proliferate in bone marrow niche and be mobilized under cellular
stress such as ischemia. Once mobilized they can home to sites of endothelial cell
damage and incorporate into newly formed blood vessels [128]. Therefore, we
examined key processes that can trigger mobilization of these progenitor cells from
the bone marrow. These processes are hypoxia induced (1) Increase in nuclear HIF1α levels (2) VEGF transcription and (3) VEGF secretion into the extracellular space.
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HIF1-α is a central mediator of revascularization. Its stabilization and nuclear
translocation leads to expression of genes such as VEGF which is essential for
mobilization of EPCs as well as sprouting, migration and proliferation of endothelial
cells to form new thin walled vessels [113]. These effects of VEGF are primarily
mediated through its receptor VEGFR2. This receptor tyrosine kinase once activated
through VEGF binding can activate diverse growth stimulatory and migratory
pathways through docking of various downstream mediators [146]. HIF1-α can also
promote immune response which is important for arteriogenesis. Hence, HIF1-α
regulation is a viable target for developing anti-ischemic therapeutics.
Under normoxic conditions it is targeted for proteasomal degradation through the
activity of prolyl hydroxylases (PHDs) which require divalent iron for their activity.
Studies have shown that inhibition of PHDs by divalent iron chelators promote
recovery from HLI through HIF1-α stabilization [198]. Based on our observation that
EPC mobilization is increased by carnosine treatment and that carnosine has the
ability to chelate divalent metals we investigated whether carnosine can stabilize
HIF1-α and increase VEGF expression.
To test whether carnosine can increase HIF1-α stabilization, we used murine
myoblast cell line C2C12 cell and determined the effect of oxygen and nutrient
deprivation on HIF1-α nuclear levels, VEGF secretion and transcription. We
investigated the effect of carnosine and its non-hydrolysable isoform octyl-Dcarnosine on HIF1-α nuclear levels and VEGF secretion. To determine if chelation
of Fe2+ by carnosine was essential for increasing nuclear HIF1-α levels, we used the
carnosine analogue, methyl carcinine, which cannot chelate Fe2+. Collectively, our
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results demonstrate that metal chelating property of carnosine increases the activity
of revascularization mediators.
Experimental Procedure
Materials: HIF 1-α (Santa-Cruz), octyl-D-carnosine and methyl carcinine (custom
made).
Fe2+ chelation by carnosine and its analogs: This was carried out based on the
principle that free Fe2+ can form a polymaltose complex with ferrozine and that this
complex can be quantified by looking at the absorbance at 560nm. In the presence
of a chelator however, some of the Fe2+ will be chelated thereby allowing for only the
left over Fe2+ to complex with ferrozine. Therefore, a decrease in absorbance at
560nm signifies chelation by the compound being investigated. The experimental
procedure is described below. Firstly, 7.5µl of 2mM FeCl2 solution was added to
277.5µL of varying concentration of the dipeptides for 3 minutes (dipeptide solutions
were prepared in water supplemented with 10% dimethylformamide). The reaction
was inhibited by adding 15µL of 5mM ferrozine solution and incubating the mixture
for 10mins at RT. Absorbance at 560nm was monitored using a spectrophotometer.
The well characterized divalent metal chelator EDTA was used as a positive control
in these experiments.
In vitro hypoxia studies:

Murine myoblast cells (C2C12) were used in these

studies. The cells were maintained in DMEM supplemented with 10% fetal bovine
serum (FBS) and 0.1% penicillin streptomycin till they were 70-80% confluent. They
were then allowed to differentiate by replacing the FBS with horse serum. First
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intracellular uptake of the various peptides (carnosine, methyl carcinine, and octyl-Dcarnosine) was obtained using LC/MS/MS (described above for carnosine
determination). To mimic ischemia in these cells, they were subjected to nutrient
deprivation by replacing the differentiation media with a solution containing 117mM
NaCl, 0.9mM CaCl2, 12mM KCl, 0.49mM MgCl2, 4mM HEPES, 20mM sodium lactate
and 5.6mM L-glucose. Also oxygen deprivation was achieved by placing cells in a
sealed humidified chamber (Billups- Rothenberg Inc) and replacing the oxygen with
95%N2 and 5%CO2. The cells were harvested at indicated times after hypoxia into
the appropriate buffer for either qRT-PCR or Western blot analysis. Hypoxia studies
were carried out for non-treated, carnosine, octyl carnosine and methyl carcinine
treated cells.
Results
Fe2+ chelation by different histidyl dipeptide: Based on our results that carnosine
augments wound healing response and literature showing carnosine has the ability
to chelate divalent metals, we next sort to delineate the contribution of metal chelation
to wound healing. Carnosine forms stable complex with transition metals such as
Cu2+ [249]. To determine whether carnosine can chelate Fe2+ which is essential for
PHD activity we determined Fe2+ chelation property using the protocol established by
Canabady et al. [197]. Our results show that carnosine exhibits metal chelation to the
same extent as EDTA (Fig. 19D). We also synthesized methyl carcinine, a carnosine
analogue that lacks the carboxyl group required for metal chelation and has a methyl
group on the imidazole nitrogen (Fig. 19A). Our results show that methyl carcinine
had little or no Fe2+ chelation property. Anserine, a naturally occurring carnosine
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analogue also showed reduced metal chelation capacity (Fig. 19D). Glycine-glycine
was used as a dipeptide control in this experiment. N.B. peptide structures are shown
in Fig 19 A-C.
Uptake of histidyl dipeptides by C2C12 (murine myoblast cells): To determine
whether the histidyl dipeptides are taken up by these cells, we incubated C2C12 cells
with carnosine(1mM), methyl carcinine(1mM) and octyl D-carnosine (100µM)
respectively at indicated times (Fig. 20 A, B). Increased intracellular concentrations
were observed for all three peptides. Also, octyl-D-carnosine treatment resulted it’s
de-esterification to carnosine (Fig. 20 A, B).
Carnosine treatment increases HIF1-  nuclear levels and VEGF secretion in
hypoxic C2C12 cells: To determine the contribution of the myocytes to the adaptive
process, we first examined time dependent changes in VEGF secretion with hypoxia
in C2C12 cells. We observed that VEGF levels were increased in conditioned media
with increasing times of hypoxia (Fig 21 A). To determine the effect of carnosine
administration on HIF1-α stabilization and signaling, we pretreated the murine
myoblasts C2C12 cells with 1mM carnosine for 12-15 h and subjected the cells to
different times of hypoxia. HIF-1 α nuclear level was increased after 1h of hypoxia
and this increase in nuclear HIF1-α was significantly enhanced by carnosine
treatment (Fig. 21B, C). VEGF secretion in the conditioned media was also increased
by carnosine treatment compared to non-treated hypoxic cells (Fig. 21 D). These
results clearly suggest that carnosine increases HIF1-α nuclear translocation and
VEGF levels.
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Octyl-D-carnosine increases HIF1-α nuclear levels and VEGF secretion: To
determine whether the whole molecule of carnosine or its constituent amino acids
increase HIF1-, we treated hypoxic C2C12 with the non-hydrolysable isoform of
carnosine, ODC (100µM). VEGF secretion and mRNA expression were increased by
ODC treatment compared with non-treated hypoxic cells (Fig 22C, D). Similarly,
nuclear levels of HIF1-α was also increased by ODC treatment (Fig 22A, B). These
observations suggest that the effect of carnosine on the angiogenic response is due
to the whole molecule and not due to constituent amino acids.
Metal chelation by carnosine contributes to VEGF secretion and HIF1-α nuclear
content: We tested the hypothesis that the increase in VEGF secretion and HIF1-α
nuclear levels by carnosine treatment is due to Fe2+ chelation by carnosine. To test
our hypothesis we pretreated C2C12 cells with methyl carcinine which lacks the ability
to chelate metals (Fig. 19D). Our results show that carnosine treatment increases
HIF1- nuclear content whereas for cells that were treated with methyl carcinine and
subjected to hypoxia there was no change in HIF1- levels compared to non-treated
cells. (Fig. 23A, B). Similarly, VEGF secretion was hindered with methyl carcinine
treatment (Fig. 23C). Taken together these results suggest metal chelation of
carnosine promotes angiogenenic response
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Figure 19: Methyl carcinine (a synthetic analog of carnosine) has reduced Fe2+
chelation. (A) Structures of different histidine dipeptides: (A) Methyl carcinine, (B)
anserine and (C) carnosine. (D) Fe2+ chelation properties of the different dipeptides
monitored by taking the absorbance at 560nm for different peptide concentrations.
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Figure 20: Time dependent increase in intracellular dipeptide levels: (A)
LC/MS/MS analysis of intracellular carnosine concentrations in C2C12 cells treated
with carnosine at the indicated times. (B) LC/MS/MS analysis of intracellular
carnosine and ODC levels after in cells treated with ODC at indicated times. NT
indicates non treated cells
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Figure 21: Carnosine treatment results in increase HIF1-α nuclear translocation
and VEGF secretion in hypoxic C2C12 cells. (A) Time dependent changes in
VEGF secretion into conditioned media following hypoxia in C2C12 cells. (B) Nuclear
HIF1-α levels in hypoxic C2C12 cells with and without carnosine treatment. (C)
Normalization of nuclear HIF1-α levels to HDAC. (D) VEGF levels in conditioned
media of treated and non-treated hypoxic cells at indicated times. Experiments were
repeated at least 3 times with n=4 for each experiment. *p <0.05 vs non-treated
hypoxic cells n=4
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Figure 22: Octyl-D-Carnosine (ODC) treatment increases HIF1-α nuclear levels
with a concomitant increase in VEGF secretion and expression. (A, B) Time
course of nuclear levels of HIF1-α with and without ODC treatment, (C) VEGF
secretion in conditioned media of hypoxic C2C12 cells (D) VEGF mRNA expression
in hypoxic C2C12 cells. Experiments were repeated at least 3 times with n=4 for each
experiment. *p <0.05 vs non-treated hypoxic cells n=4

118

Figure 23
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Figure 23: Metal chelation by carnosine promotes HIF1-α stabilization: (A, B)
HIF1-α nuclear levels in C2C12 cells subjected to 1h of hypoxia with carnosine (car),
methyl carcinine (MC) or no treatment (NT). (C) VEGF secretion in conditioned media
of hypoxic C2C12. *p <0.05 vs non-treated hypoxic cells n=4
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Discussion
The major goal of this study was to identify the mechanisms by which carnosine
regulates HIF1-α and increases VEGF levels. Using an in-vitro model of hypoxia
and nutrient deprivation we observed that HIF1-α nuclear levels and VEGF
secretion was enhanced with increasing length of hypoxia and peaked at 1h and
6h respectively. This effect was significantly enhanced by carnosine treatment
suggesting that carnosine stabilizes HIF1-α.
We investigated the contribution of metal chelation by carnosine to HIF1-
stabilization. Carnosine is a multifunctional compound with functions such as metal
chelation, pH buffering and aldehyde quenching [202]. NMR studies have shown
that carnosine interacts with divalent metals through 2 imidazole nitrogen, peptide
bond, carboxylic acid and primary amino group [196]. However, one imidazole
nitrogen and the amino group are critical for pH buffering and aldehyde quenching
respectively [250, 251]. Therefore, to prevent metal chelation without influencing
aldehyde quenching or pH buffering, we synthesized methyl carcinine an analogue
of carnosine without a carboxylate group and with a methyl group on imidazole
nitrogen. Analysis of pka values shows that pH buffering was not altered
significantly with these modifications since a pKa of 6.61 was observed for methyl
carcinine compared to 6.75 for carnosine. Metal chelating capacity of this
compound was significantly decreased compared to carnosine.
Using in vitro model of ischemia we found that, HIF1-α nuclear content and VEGF
secretion was significantly increased with carnosine treatment, whereas for
hypoxic cells treated with methyl carcinine, no change in HIF1- levels was
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observed compared to the non- treated cells. Our results are in line with previous
studies showing that Fe2+ chelation promote recovery from HLI [198]. However,
the use of carnosine has an added benefit because this dipeptide targets diverse
pathways such as ROS-induced inflammation, lipid peroxidation and acidosis.
Carnosine can be hydrolyzed to -alanine and histidine by carnosinase. Previous
studies have shown that decarboxylation of histidine generates histamine [252]
which is an important regulator of hematopoiesis, immune cells function and
revascularization [253]. Hence, to determine the possible contribution of carnosine
hydrolysis in hypoxic adaptation we used a non-hydrolysable octyl D-isoform of
carnosine (ODC). We observed a similar effect of ODC on HIF-1α levels and
VEGF transcription as observed with the L-isoform suggesting that histidinedecarboxylation did not contribute to increase in HIF1-α activity. This is particularly
important because the effect of this axis on carnosine’s anti-ischemia effect is
conflicting [252, 254].
In summary, our study identified that Fe2+ chelation by carnosine is important for
regulating HIF1-α nuclear content. The increase in HIF1-α nuclear levels likely
increases revascularization in carnosine treated HLI mice.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
Concluding discussion
The purpose of this study was to investigate the therapeutic potential of carnosine,
a naturally occurring component of food, in critical limb ischemia. Recent data from
developed and developing countries estimated that >200 million people worldwide
and approximately 8 million people in United States have PAD [2, 6]. Both
symptomatic and asymptomatic PAD patients have an increased risk of mortality,
morbidity and lower quality of life [7]. With the increasing incidence of type 2
diabetes (T2D) and rising aging population the number of PAD patients is likely to
increase [2]. Because PAD is an under-recognized disease, few medications are
available to improve functional performance in these patients. Although surgical
revascularization is an amenable treatment, low graft patency and restenosis limits
its utility in these patients [175]. Therefore to adequately compensate these
patients current emphasis is to increase therapeutic angiogenesis and
arteriogenesis in the ischemic limb. This is expected to improve walking ability and
quality of life in these patients. Hence, we tested the hypothesis that carnosine will
promote post-ischemic angiogenesis and arteriogenesis through aldehyde
quenching and metal chelation. To address this hypothesis, we determined
whether carnosine supplementation would increase tissue reperfusion after
hindlimb ischemia surgery.
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In Chapter II, we demonstrated by Laser Doppler perfusion imaging and microfil
perfusion-microCT analysis that carnosine treatment increases tissue perfusion
and vascular volume. We also showed that tissue injury was reduced, and limb
function significantly improved by carnosine feeding. Based on these observations
we concluded that supplementation of carnosine improves revascularization after
limb ischemia.
Having established that carnosine improves blood flow in the ischemic limb we
next examined the effect of ischemia on endogenous carnosine synthesis,
hydrolysis and transport. LC/MS/MS analysis of the ischemic limb showed that
there was no change in carnosine levels by HLI surgery however, levels of
carnosine were increased in the ischemic limb of mice supplemented with
carnosine. qRT-PCR analysis demonstrated that levels of carnosine transporter,
PHT1, was increased in the ischemic limb of carnosine treated mice. These results
established that oral carnosine supplementation increases carnosine levels in the
ischemic limb by increasing the expression of transporters.
Next we evaluated the effect of this increase in muscle carnosine on the adaptive
response to ischemia. We observed an increase in VEGF levels which was
associated with increased levels of circulating EPCs and decreased bone marrow
EPCs. This suggests a possible VEGF dependent mechanism regulating EPC
exodus from the bone marrow niche.
Urinary analysis of the mice subjected to HLI showed that extrusion of carnosineacrolein conjugates was increased by carnosine supplementation. Similarly, levels
of carnosinylated proteins adduct were increased in the ischemic limb of carnosine
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treated mice. These results suggests that increased extrusion of aldehyde
conjugates and carnosinylation of proteins decreases carbonyl stress in carnosine
treated mice. These reports demonstrate a direct involvement of carnosine in the
adaptive response to ischemia and suggest a direct potential benefit of increasing
muscle carnosine levels.
As mentioned, ROS generation is increased in reperfusion [33, 49]. It has been
suggested that some of the secondary and metastable products derived from ROS
amplify their effects. In this process several highly reactive lipid peroxidation
products are generated that can be removed by enzymes aldose reductase,
aldehyde dehydrogenase, and glutathione S transferases. However, under
diseased conditions these pathways are overwhelmed and thus unsaturated
aldehydes increasingly react with amino acid residues of proteins. Recently, it has
been shown that carnosine administration has a sparing effect on antioxidant
systems such as serum superoxide and glutathione peroxidase since the levels of
these enzymes are increased with carnosine treatment [245]. We also show that
protein-HNE adducts that were increased with ischemia were reduced when
carnosine was administered to the ischemic mice. Although carnosine is an
effective quencher of HNE, glutathione S-transferaseA4 also affects this highly
reactive metabolite through the process of glutathionylation. However, recent
studies have shown that glutathione derivative of HNE can induce excessive
macrophage inflammation through TNF-α and NF-κB pathways. Furthermore, use
of these enzymes by viral transduction as therapies are still in infancy. Therefore,
our results showing that supplementation of carnosine improves revascularization
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has a selective advantage as a therapeutic option for ischemia [255]. Carnosine
neither exacerbate nor attenuates the inflammatory response but still prevents
tissue injury induced by ischemia and increases neovascularization response.
In Chapter III we demonstrate that VEGF levels are increased in the ischemic limb
of the carnosine treated mice. Therefore, we investigated the role of metal
chelation by carnosine on this process. We hypothesized that metal chelation by
carnosine will stabilize HIF1-α through prolyl hydroxylase inhibition and increase
VEGF expression. To determine the contribution of metal chelation we synthesized
methyl carcinine, an analogue of carnosine which has diminished metal chelation
ability. Using in vitro model of oxygen and nutrient deprivation our results show
that there was no change in HIF1-α nuclear levels by methyl carcinine treatment
compared to non-treated cells. We further determined whether hydrolysis of
carnosine by carnosinase and subsequent decarboxylation of histidine to
histamine is involved in regulating nuclear levels of HIF1-α . We used octyl-Dcarnosine a non-hydrolysable isoform of carnosine. Our results show that octyl-Dcarnosine was equally effective as carnosine in increasing nuclear HIF1-α levels.
Collectively our results demonstrate that carnosine increases revascularization in
murine hindlimb ischemia. We show that HIF1-α stabilization and VEGF secretion
may be critical for these responses. Further we established that metal chelation
and aldehyde quenching by carnosine are critical for promoting revascularization.
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Limitations and Future Directions
Mechanistic Consideration
The results from this study has revealed insights into the mechanisms by which
carnosine can increase revascularization responses, however, other mechanistic
questions remain to be answered. We showed that carnosine treatment increases
nuclear levels of HIF1-α and observed an increase in VEGF levels. We therefore
concluded that the increase in HIF1-α could account for the increase in VEGF
since VEGF is a transcriptional target. Although VEGF transcription is highly
documented to be regulated by HIF1-α

we did not test this directly in our

experiments. Pharmacological inhibition HIF1-α or used of HIF1-α knockdown
cells will be essential to identify if changes in VEGF obtained with carnosine
treatment is attributable to HIF1-α only.
Also, we identified that Fe2+ chelation by carnosine is essential for regulating
nuclear HIF1-α content however, it will be important to establish which upstream
targets are being regulated by this process. Prolyl hydroxylases involved in
targeting HIF1-α for proteasomal degradation require Fe2+ of activity.
Measurement of prolyl hydroxylase activity with and without carnosine treatment
will strengthen our understanding and establish whether the increase in nuclear
content was as a result direct inhibition of prolyl hydroxylase. Likewise using
tagged HIF1-α we can directly measure its translocation in our model. Current
dogma in the field states that following prolyl hydroxylase inactivation, HIF1-α is
nuclearly translocated

and binds to hypoxia response elements to induce
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transcription of target genes [113]. Using labelled or tagged HIF1-α we can directly
measure its stabilization and subsequent nuclear translocation in future studies.
Recent evidence has documented a role for NO and ROS in HIF1-α stabilization
in an oxygen independent manner [256]. Divalent metal chelation by carnosine can
limit reactive oxygen and nitrogen species generation [257] thereby increasing
HIF1-α stability. It will be important to identify which of these processes regulates
HIF-1α stability.
Secondly, during ischemia the increased reliance on glycolysis leads to acidosis
due to proton accumulation from lactic acid decomposition. Since carnosine is a
pH buffering agent, supplementation may increase glycolysis in the ischemic
tissues. Hence evaluating the role of pH buffering of carnosine in ischemic
adaptations will provide insight into the mechanisms by which carnosine
attenuates wound healing responses.
Our immunohistochemistry data shows that carnosine increases muscle
regeneration after ischemia. Mammals have a highly orchestrated system of
skeletal muscle regeneration. This process involves activation of muscle resident
satellite cells through transcription factors MyoD and Myf5. Other factors such as
Pax3 and Pax7 are also involved in regeneration [258]. Recently, signal transducer
and activator of transcription 3 (STAT3) signaling pathway was shown to be
involved in muscle regeneration. Studies have shown that this pathway is
important to ensure survival, activation and proliferation of satellite cells into fully
differentiated myotubules [259, 260]. Interestingly, carnosine has been shown to
activate this pathway in neuronal cell after cerebral ischemia [261]. Thus,
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understanding the regulation of this pathway by carnosine in the context of muscle
ischemia may be important in understanding how it regulates muscle regeneration.
Lastly, as outlined in chapter I several cell types such as endothelial, smooth
muscle, muscle and immune cells are involved in the ischemic response. In this
study we determined the responses in ischemic muscle which promotes recovery
by carnosine supplementation. Future studies are needed to establish how
endothelial cells respond to carnosine treatment e.g. assays to measure tube
formation and scratch assay. Similarly, paracrine signaling between muscle and
endothelial cells can be determined by treating the myoblasts with carnosine and
treating human umbilical vascular endothelial cells (HUVECs) with conditioned
media from carnosine treated cell to determine changes in tube formation.
Clinical Application
In this study we laid the foundation for carnosine to be used as a viable therapy for
critical limb ischemia however, several questions need to be answered before it
can be fully translational. Further studies are needed to determine the optimal
dose, mode and frequency of administration. One of the limitations of this hindlimb
ischemia model is that the studies were conducted in healthy mice with no
comorbid conditions. This clearly is not the case in the human patient populations.
PAD patients have other diseases such as cardiovascular disease, diabetes which
can inversely affect the reparative response. Further studies evaluating the effect
of carnosine on revascularization in the presence of one or more of these risk
factors will be important in elucidating the true therapeutic potential of carnosine.
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Secondly, β-alanine is the rate limiting substrate for carnosine synthesis. This
amino acid is predominantly obtained from pyrimidine degradative pathway.
Diverse polymorphisms exist in human populations for the rate-limiting enzyme
dihydropyrimidine dehydrogenase that is involved in the synthesis of β-alanine.
These polymorphisms have been studied in the context of chemotherapy
administration where deficiencies lead to severe toxicity and death [262]. Recent
epidemiological work suggests that genetics could be playing an important role in
the development of PAD however most of the candidate genes have not been
identified [7]. Therefore, based on these established polymorphisms and the
known benefits of carnosine and studies showing diminished carnosine levels in
patients with cardiovascular risk factors like diabetes, it may be important to
evaluate the possible contributions of these polymorphisms to carnosine levels.
Also, associations between these polymorphisms and cardiovascular disease
development may be important in predicting patients who may develop PAD and
selecting patients which may benefit from carnosine therapy.
Lastly, most of the key pathways involved in muscle ischemia are similar in cardiac
or cerebrovascular ischemia. Therefore, although this work studied carnosine in
the context of critical limb ischemia it can also be utilized in other forms of tissue
ischemia.
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Figure 24
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Figure 24: Schematic overview of mechanism by which carnosine improves
revascularization: Carnosine supplementation increases muscle carnosine
content. This leads to HIF-1α stabilization presumably through PHD inhibition and
VEGF expression. VEGF acting through its receptor increases EPC mobilization
and homing to the ischemic tissue leading to neovascularization.
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